

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C. 20231
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 20 April 2000 (20.04.00)	
International application No. PCT/EP99/06692	Applicant's or agent's file reference 23143 WO
International filing date (day/month/year) 10 September 1999 (10.09.99)	Priority date (day/month/year) 11 September 1998 (11.09.98)
Applicant FEIX, Günter et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

03 March 2000 (03.03.00)

☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).


The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer R. E. Stoffel Telephone No.: (41-22) 338.83.38
--	--

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)





Applicant's or agent's file reference 23143 WO		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP99/06692	International filing date (day/month/year) 10/09/1999	Priority date (day/month/year) 11/09/1998
International Patent Classification (IPC) or national classification and IPC C07K14/43		
Applicant AGRICULTURAL TECHNOLOGY & GENETICS GMBH et al.		

- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 6 sheets, including this cover sheet.
 - ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 5 sheets.

- This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 03/03/2000	Date of completion of this report 16. 01. 01
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Wimmer, G Telephone No. +49 89 2399 7347 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/06692

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

Description, pages:

1-44 as originally filed

Claims, No.:

1-29 as received on 04/12/2000 with letter of 04/12/2000

Drawings, sheets:

1/5-5/5 as originally filed

Sequence listing part of the description, pages:

37-44, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/06692

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-3, 10-17, 20, 22-29
	No:	Claims	4-9, 18-19, 21
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-29
Industrial applicability (IA)	Yes:	Claims	
	No:	Claims	24, 27, 28

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/06692

R l t m V

Reasoned statement under Art. 35(2) PCT with regard to novelty, inventive step or industrial applicability.

The application does not meet the requirements of Art. 33 PCT since **claims 4-9, 18-19 and 21 are not novel**, and **claims 1-29 do not appear to contain an inventive step**.

1) Reference is made to the following document:

D1: GODDEMEIER M L ET AL., : 'Root-specific expression of a *Zea mays* gene encoding a novel glycine-rich protein, zmGRP3.' PLANT MOLECULAR BIOLOGY, vol. 36, no. 5, March 1998 (1998-03), page 799-802 XP002128334

The validity of the priority date claimed for sequences SEQ ID NOs 1-15 has not been assessed. In case priority is later found to be invalid, document D6 as listed in the international search report (XP002128339) would be regarded as prior art for the purpose of examination of the claims.

Novelty under Art. 33(2) PCT.

- 2) Nucleic acid sequences of 70% or more identity to any of the sequences SEQ ID NOs 1-11 do not appear to be disclosed in the prior art. Consequently, claims 1-3 can be regarded as novel.
- 3) Document D1 discloses the entire *Zea mays* zmGRP3 gene, including some of the 3' untranslated region. This latter region is >87% identical to sequences overlapping with 413 bases of SEQ IDs 12 and 13.
Since the sequence of D1 therefore contains a subsequence which is >80% identical to the entire 440 bases of SEQ ID 13, claim 4 in its second aspect is not novel.
- 4) Consequently, the sequence of D1 also anticipates claims 5-8, since the sequence described had to be cloned using vectors; claims 5-8 therefore lack novelty.
Likewise, claim 9 is not novel, since also the zmGRP3 gene can be viewed as conferring "a character of agronomic or industrial benefit".
- 5) According sequences, linked to one of the genes listed in claim 10, have not been

disclosed. Also, additional regulatory elements were not described for the vector of D1. Claims 10-17 can therefore be regarded as novel.

Since the vector of D1 was obviously introduced into bacterial cells, claims 18, 19 and 21 lack novelty.

Claims 20 and 22-29 can be regarded as novel.

Inventive Step under Art. 33(3) PCT.

- 6) Claim 1 is directed to sequences which are 5' of the coding region of the *Zea mays* zmGRP3 gene.

Document D1 already discloses the coding region of this gene, and some of the 3' untranslated region. The authors of D1 describe this gene to be specifically expressed in the root system. The difference, and therefore the technical problem solved by the application, was to provide the regulatory sequences responsible for this effect.

However, the solution, the provision of 5' and 3' untranslated regions, cannot be viewed as being inventive.

It is common knowledge that sequences which act regulatory to the expression of a given gene are found primarily in the 5' and 3' untranslated regions, since promoter structures, polyadenylation and other signal sequences are found in those regions. The skilled person would therefore use standard techniques, based on sequences as disclosed in D1, to isolate genomic 5' and 3' sequences of the gene. The skilled person would then use these sequences to test the expression of a reporter gene in various plant tissues.

No inventive step can therefore be acknowledged for the provision of sequences SEQ IDs 1-15. Consequently, claims 1-5 lack an inventive step.

- 7) Additional features in claims 6-23 are trivial extensions, and do not make these claims inventive. Likewise, methods according to claims 24-29 represent obvious applications, and are not inventive.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/06692

Industrial Applicability under Art. 33(4) PCT.

- 8) Although humans were apparently not intended as target organisms for the methods of claims 24, 27 and 28, they are not explicitly excluded. This is considered to be contrary to morality and hence not allowable.

Re Item VIII

Certain observations and clarity.

The feature of claim 5, "which is derived from maize", does not define subject-matter since a given nucleic acid is defined by its nucleotide sequence, and the product does not allow to determine from which organism it was originally isolated.

Furthermore, the term "derived from" is ambiguous, since without further limitation, basically *any* nucleotide sequence can be regarded to be derived from any other.

Gl iss & GroßePatentanwälte
München Stuttgart**Claims**

1. A nucleic acid sequence for use in cloning and expressing a root specific nucleic acid sequence in a plant which is selected from the group consisting of
 - a) the nucleic acid sequence set out in SEQ ID No. 1 or a complementary strand thereof,
 - b) a nucleic acid sequence which has a degree of identity of more than 70 % to the nucleic acid sequence defined in (a) and
 - c) alleles of the nucleic acid sequence defined in (a) or (b).
2. The nucleic acid sequence of claim 1 which is selected from the group consisting of
 - a) the nucleic acid sequence set out in SEQ ID No. 2 or a complementary strand thereof,
 - b) a nucleic acid sequence which has a degree of identity of more than 70 % to the nucleic acid sequence defined in (a) and
 - c) alleles of the nucleic acid sequences defined in (a) or (b).

-2-

3. The nucleic acid sequence according to claim 1 or 2, which is selected from the group consisting of
 - a) the nucleic acid sequence set out in any one of SEQ ID No. 3 to 11 or a complementary strand thereof,
 - b) a nucleic acid sequence which has a degree of identity of more than 70 % to the nucleic acid sequence defined in (a) and
 - c) alleles of the nucleic acid sequence defined in (a) or (b).
4. A nucleic acid sequence for use in cloning and expressing a root specific gene in a plant which is selected from the group consisting of
 - a) the nucleic acid sequence set out in any one of SEQ ID No. 12 to 15 or a complementary strand thereof,
 - b) a nucleic acid sequence which has a degree of identity of more than 70 % to the nucleic acid sequences defined in (a) and
 - c) alleles of the nucleic acid sequence defined in (a) or (b).
5. The nucleic acid sequence of any one of the preceding claims, which is derived from maize.
6. A vector comprising the nucleic acid sequence of any one of the preceding claims.

-3-

7. The vector of claim 6, which is a bacterial or viral vector.
8. The vector of any one of claims 6 or 7, wherein the nucleic acid sequence of any one of claims 1 to 5 is operably linked to a gene of interest.
9. The vector of claim 8, wherein the gene of interest is chosen from a gene which confers a character of agronomic or industrial benefit.
10. The vector of claim 9, wherein the gene which confers a character of agronomic or industrial benefit is a gene for resistance to infection by a virus, a gene conferring resistance to a herbicide or to an insecticide or, alternatively, a gene whose expression confers male sterility.
11. The vector of any one of claims 6 to 10, which comprises further regulatory elements directing or enhancing the expression of the gene of interest.
12. The vector of any one of claims 6 to 11, wherein the further regulatory elements are 5', 3' or 5' and 3' elements.
13. The vector of claim 12, wherein the 3' regulatory element is the poly A addition sequence of the NOS gene of *Agrobacterium tumefaciens*.
14. The vector according to any one of claims 6 to 13, which furthermore contains T-DNA.

-4-

15. The vector of claim 14, which contains the left, the right or both T-DNA borders.
16. The vector according to claim 14 or 15, wherein the nucleic acid sequence is located within the T-DNA or adjacent to it.
17. The vector according to claim 16, wherein the nucleic acid sequence in conjunction with the gene of interest is located within the T-DNA or adjacent to it.
18. A host cell containing the vector of any one of claims 6 to 17.
19. The host cell of claim 18, which is a plant, yeast or bacterial cell.
20. The host cell of claim 19, which is a cell from a monocotyledonous or dicotyledonous plant.
21. A cell culture comprising a cell according to any one of claims 18 to 20.
22. A plant comprising a host cell according to any one of claims 18 to 20.
23. Seeds, propagation material, harvest material and plant tissue, comprising a host cell according to any one of claims 18 or 20 or derived from a plant according to claim 22.
24. A method of genetically modifying a cell by transforming a cell with a nucleic acid sequence according to any one of claims 1 to 5 or a vector according to any one of claims 6 to

-5-

- 17, wherein the gene of interest contained in the vector is expressible in the cell.
25. The method of claim 24, wherein the cell is a plant, bacterial or yeast cell.
26. The method of claims 24 or 25, wherein the transformed cell is regenerated into a differentiated plant.
27. The method of any one of claims 24 to 26, wherein the cell is transformed by transfer of a vector or nucleic acid sequences from a bacterium to the cell.
28. The method of any one of claims 24 to 27, wherein the cell is transformed by direct intake of a nucleic acid sequence or a vector, by microinjection or particle bombardment with a nucleic acid sequence or a vector.
29. A method for isolating a root specific gene and/or root specific regulatory element from a plant, whereby a nucleic acid sequence of any one of claims 1 to 5 or a vector of any one of claims 6 to 17 is used to screen nucleic acid sequences derived from the plant.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/43, C12N 15/29, 15/10, 15/82, A01H 01/00	A1	(11) International Publication Number: WO 00/15662 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/EP99/06692 (22) International Filing Date: 10 September 1999 (10.09.99) (30) Priority Data: 98117251.3 11 September 1998 (11.09.98) EP (71) Applicant (for all designated States except US): AGRICULTURAL TECHNOLOGY & GENETICS GmbH [DE/DE], Im Rheinfeld 1-13, D-76437 Rastatt (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): FEIX, Günter [DE/DE]; Rehagweg 13, D-79100 Freiburg (DE). WULFF, Doerte [DE/DE]; Buchenstrasse 10, D-79108 Freiburg (DE). (74) Agents: SCHRELL, Andreas et al.; Maybachstrasse 6A, D-70469 Stuttgart (DE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: REGULATORY SEQUENCES FOR ROOT SPECIFIC OR ROOT ABUNDANT GENE EXPRESSION IN PLANTS		
(57) Abstract <p>The present invention relates to regulatory elements for tissue specific, in particular root specific, expression of genes of interest in plants. The invention also relates to methods to obtain transgenic plants which show root specific expression of genes of interest and to methods for isolating root specific genes and/or root specific regulatory elements.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Regulatory Sequences for Root Specific or Root Abundant Gene Expression in Plants

Description

The present invention relates to isolated regulatory elements, in particular promoters and 3' regulatory elements, that drive root specific or root abundant expression in plants, in particular in monocotyledonous plants, to vectors containing the regulatory elements, to host cells containing the vectors, to plants containing the host cells and to methods for isolating regulatory elements that contribute to tissue-preferred gene expression in plants.

Gene expression is considered to comprise a number of steps from the DNA to the final protein product. Initiation of transcription of a gene is generally believed to be the predominant controlling factor in determining expression of a gene. The transcriptional controls are generally located in relatively short sequence elements embedded in the 5'-flanking and/or 3'-flanking region of the transcribed gene with which DNA-binding proteins may interact. These DNA sequence elements serve to promote the formation of transcriptional complexes and eventually initiate gene expression processes. It is furthermore known that the regulation of gene expression often depends upon the development stage and the tissue specificity of the cell concerned. Thus, certain tissues of organisms such as plants may exhibit a metabolism and a protein composition different from other tissues of the plant or different from the same tissue in a different developmental stage.

- 2 -

Controlling the expression of genes in transgenic plants is considered to have high commercial value. The ability to control gene expression is useful for conferring resistance and immunity to certain diseases or to modify the metabolism of the tissue. The transfer of heterologous genes or genes of interest into a plant under control of tissue-specific genes provides a powerful means of conferring selective advantages to plants and to increase their commercial value.

It is also considered particularly important to develop transcriptional regulatory units that direct gene expression selectively to root tissue. Root preferred gene expression will provide several advantages to a plant, such as alteration of the function of the root tissue; modification of the growth rate; resistance to root preferred pathogens, pests, herbicides or adverse weather conditions; as well as broadening the range of soils or environments in which said plant may grow. Root abundant or root specific gene expression would provide a mechanism according to which morphology and metabolism may be altered to improve the yield and to produce useful proteins in greater amounts.

Thus, there is a need to provide regulatory elements capable of directing transcription specifically in root tissue. WO97/44448 describes promoter elements conferring root preferred gene expression. The disclosed promoter elements were obtained from maize seedlings. However, the isolated promoter elements may not be suitable for any desired transformation problem.

Furthermore, WO94/02619 discloses regulatory sequences for root specific or root abundant gene expression derived from Brassica sp. However, this promoter was not shown to work in monocotyle-

- 3 -

donous plants with an efficiency great enough to provide means for commercial use.

Thus, the technical problem underlying the present invention is to provide novel regulatory elements for use in cloning and expressing root specific or root abundant genes, in particular for use in monocotyledonous plants which provide a high expression efficiency together with a high tissue specificity.

The present invention solves the technical problem underlying the present invention by providing purified and isolated new nucleic acid sequences for use in cloning and expressing a root specific or root abundant gene in a plant which are selected from the group consisting of

(a) the nucleic acid sequence set out in SEQ ID No. 1 or a part or complementary strand thereof,

(b) a nucleic acid sequence which hybridizes to the nucleic acid sequence defined in SEQ ID No. 1 or a complementary strand thereof and

(c) alleles or derivatives of the nucleic acid sequence defined in (a) or (b) or a complementary strand thereof.

In particular, the problem is solved by providing a purified nucleic acid sequence according to the above wherein the sequence is selected from the group consisting of (a1) the nucleic acid sequence set out in SEQ ID No. 2 or a part or complementary strand thereof, (b1) a nucleic acid sequence which hybridizes to the nucleic acid sequence defined in SEQ ID No. 2 and (c1) alleles or derivatives of the nucleic acid sequence defined in (a1) or (b1).

In a further particularly preferred embodiment, the problem is solved by providing a purified nucleic acid sequence according to the above which is selected from the group consisting of (a2) the nucleic acid sequence set out in any one of SEQ ID Nos. 3 to 11, (b2) a nucleic acid sequence which hybridizes to any one of the nucleic acid sequences defined in any one of SEQ ID Nos. 3 to 11 and alleles or derivatives of the nucleic acid sequence defined in (a2) or (b2).

The invention also relates to purified nucleic acid sequences for use in cloning and expressing a root specific or root abundant gene in a plant that are selected from the group consisting of (a3) the nucleic acid sequence set out in any one of SEQ ID No. 12, 13, 14 or 15 or a part or complementary strand thereof, (b3) a nucleic acid sequence hybridizing to any one of the sequences defined in (a3) and (c3) alleles or derivatives of the nucleic acid sequences defined in (a3) or (b3).

The sequences set out in SEQ ID No. 1 to 11 comprise isolated 5' regulatory elements and are considered to be promoters or parts thereof, i.e. promoter elements. These sequences are capable of modulating, initiating and/or contributing to the transcription of nucleic acid sequences operably linked to them. In a preferred embodiment of the present invention these sequences may additionally contain at their 3' terminus the nucleotide sequence from position 1761 to 1780 as depicted in SEQ ID No. 14, which is CCTGGACTCG CTCACTGGCA.

The sequences set out in SEQ ID No. 12, 13 and 15 comprise isolated 3' regulatory elements and are considered to be 3' transcription regulatory elements, or parts thereof, for instance polyadenylation signals. The sequences of SEQ ID Nos. 12 and 15

- 5 -

linked in 5' to 3' direction to each other represent the complete 3' regulatory element of the present invention.

These sequences are capable of modulating, in particular contributing to, or terminating the transcription of nucleic acid sequences operably linked to them.

The sequence set out in SEQ ID No. 14 is a genomic clone comprising all of the above sequences except the 3' regulatory element of the SEQ ID No. 15.

The present invention also relates to nucleic acid sequences which hybridize, in particular under stringent conditions, to the sequences set out in any one of SEQ ID No. 1 to 15. In particular, these sequences have a degree of identity of 70% to the sequence of SEQ ID Nos. 1 to 15.

In the context of the present invention, nucleic acid sequences which hybridise to any one of the specifically disclosed sequences of SEQ. Id. Nos. 1 to 15 are sequences which have a degree of 60% to 70% sequence identity to the specifically disclosed sequence on nucleotide level. In an even more preferred embodiment of the present invention, sequences which are encompassed by the present invention are sequences which have a degree of identity of more than 70% or 80% and even more preferred more than 90%, 95% or 99% to the specifically disclosed sequences on nucleotide level.

The present invention also relates to nucleic acid sequences which encode proteins wherein the amino acid sequence of the proteins have a degree of identity of 66% to 90% on amino acid level, most preferably a degree of identity of more than 90%, 95% or 99% identity on amino acid level.

- 6 -

Thus, the present invention relates to nucleic acid sequences, in particular DNA sequences which hybridise under the following conditions to the sequences specifically disclosed:

Hybridisation buffer: 1 M NaCl; 1% SDS; 10%
dextran sulphate; 100 μ g/ml ssDNA
Hybridisation temperature: 65° C
First wash: 2 x SSC; 0.5% SDS at room
temperature
Second wash: 0.2 x SSC; 0.5% SDS at 65°C.

More preferably, the hybridisation conditions are chosen as identified above, except that a hybridisation temperature and second wash temperature of 68° C, and even more preferred, a hybridisation temperature and second wash temperature of 70° C is applied.

Thus, the present invention also comprises functionally equivalent nucleic acid sequences to the sequences of any one of SEQ ID No. 1 to 15, in particular sequences which have at least homology to the sequence of SEQ ID No. 1 to 15. The invention also relates to alleles and derivatives of the sequences mentioned above which are defined as sequences being essentially similar to the above sequences but comprising, for instance, nucleotide exchanges, substitutions (also by unusual nucleotides), rearrangements, mutations, deletions, insertions, additions or nucleotide modifications and are functionally equivalent to the sequences set out in SEQ ID No. 1 to 15.

The nucleic acid sequences of the present invention are, in a preferred embodiment, derived from maize (*Zea mays*), most preferably from maize roots.

The nucleic acid sequences of the present invention are useful for cloning tissue specific, in particular root specific nucleic acid sequences, in particular regulatory elements and/or genes, in plants, in particular in monocotyledonous plants. Thus, the present invention provides the means for isolation of transcription regulatory elements that direct or contribute to tissue-preferred gene expression in plants, in particular in monocotyledonous plants, such as maize. The present invention also provides the means of isolating tissue specifically expressed genes, in particular root specifically expressed genes and their transcripts.

The nucleic acid sequences of the present invention are also useful for expressing genes of interest in plants, in particular in the roots of plants and especially in the roots of monocotyledonous plants such as maize or of dicotyledonous plants such as sugar beets (*Beta vulgaris*). Thus, the present invention provides the means to direct the expression of a gene of interest in a tissue-specific or tissue-abundant manner in roots, for instance in roots of seedlings. Accordingly, the proteins encoded by the gene of interest can be accumulated in roots. For instance, the promoter of the present invention is particularly useful in driving the transcription of heterologous structural genes that confer disease immunity or resistance to disease-susceptible roots.

In the context of the present invention, a number of terms shall be utilized as follows.

In the context of the present invention the term "disease" encompasses any adverse condition caused to a plant by a virus or

an organism other than itself, such as fungi, bacteria and insects.

The term "promoter" refers to a sequence of DNA, usually upstream (5') to the coding sequence of a structural gene, which controls the expression of the coding region by providing the recognition for RNA polymerase and/or other factors required for transcription to start at the correct site. Promoter sequences are necessary, but not always sufficient to drive the expression of the gene. A "promoter element" constitutes a fraction of the DNA sequence of the promoter.

A "3' regulatory element (or "3' end") refers to that portion of a gene comprising a DNA segment, excluding the 5' sequence which drives the initiation of transcription and the structural portion of the gene, that determine the correct termination site and contains a polyadenylation signal and any other regulatory signals capable of effecting messenger RNA (mRNA) processing or gene expression. The polyadenylation signal is usually characterized by effecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. Polyadenylation signals are commonly recognised by the presence of homology to the canonical form 5'-AATAA-3', although variations are not uncommon.

"Nucleic acid" refers to a large molecule which can be single or double stranded, composed of monomers (nucleotides) containing a sugar, phosphate and either a purine or pyrimidine. The nucleic acid may be cDNA, genomic DNA, or RNA, for instance mRNA.

The term "nucleic acid sequence" refers to a natural or synthetic polymer of DNA or RNA which may be single or double stranded, alternatively containing synthetic, non-natural or al-

tered nucleotide bases capable of incorporation into DNA or RNA polymers.

The term "gene" refers to a DNA sequence that codes for a specific protein and regulatory elements controlling the expression of this DNA sequence.

The term "regulatory element" refers to a sequence located upstream (5'), within and/or downstream (3') to a coding sequence whose transcription and expression is controlled by the regulatory element, potentially in conjunction with the protein biosynthetic apparatus of the cell. "Regulation" or "regulate" refer to the modulation of the gene expression induced by DNA sequence elements located primarily, but not exclusively upstream from (5') the transcription start of the gene of interest. Regulation may result in an all or none response to a stimulation, or it may result in variations in the level of gene expression.

The term "coding sequence" refers to that portion of a gene encoding a protein, polypeptide, or a portion thereof, and excluding the regulatory sequences which drive the initiation or termination of transcription. The coding sequence or the regulatory element may be one normally found in the cell, in which case it is called "autologous", or it may be one not normally found in a cellular location, in which case it is termed a "heterologous gene" or "heterologous nucleic acid sequence". A heterologous gene may also be composed of autologous elements arranged in an order and/or orientation not normally found in the cell in which it is transferred. A heterologous gene may be derived in whole or in part from any source known to the art, including a bacterial or viral genome or episome, eukaryotic nuclear or plasmid DNA, cDNA or chemically synthesized DNA. The structural gene may constitute an uninterrupted coding region or

- 10 -

it may include one or more introns bounded by appropriate splice junctions. The structural gene may be a composite of segments derived from different sources, naturally occurring or synthetic.

The term "vector" refers to a recombinant DNA construct which may be a plasmid, virus, or autonomously replicating sequence, phage or nucleotide sequence, linear or circular, of a single or double stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell, in particular a plant cell.

As used herein, "plant" refers to photosynthetic organisms, such as whole plants including algae, mosses, ferns and plant-derived tissues. "Plant derived tissues" refers to differentiated and undifferentiated tissues of a plant, including roots, shoots, shoot meristems, coleoptilar nodes, tassels, leaves, cotyledonous petals, pollen, ovules, tubers, seeds, kernels and various forms of cells in culture such as intact cells, protoplasts, embryos and callus tissue. Within the context of the present invention, the term "root" includes various groups of primary, lateral seminal or crown roots, and root tips. Plant-derived tissues may be in planta, or in organ, tissue or cell culture. A "monocotyledonous plant" refers to a plant whose seeds have only one cotyledon, or organ of the embryo that stores and absorbs food. A "dicotyledonous plant" refers to a plant whose seeds have two cotyledons.

As used herein, "transformation" refers to the process by which cells, tissues or plants acquire properties encoded on a nucleic

acid molecule that has been transferred to the cell, tissue or plant.

"Transformation" and "transferring" refers to methods to transfer DNA into cells including, but not limited to, particle bombardment, microinjection, permeabilizing the cell membrane with various physical (e.g., electroporation) or chemical (e.g., polyethylene glycol, PEG) treatments.

The term "host cell" refers to a cell which has been genetically modified by transfer of a heterologous or autologous nucleic acid sequence or its descendants still containing this sequence. These cells are also termed "transgenic cells". In the case of an autologous nucleic acid sequence being transferred, the sequence will be present in the host cell in a higher copy number than naturally occurring.

The term "operably linked" refers to the chemical fusion of two or more fragments of DNA in a proper orientation such that the fusion preserves or creates a proper reading frame, or makes possible the proper regulation of expression of the DNA sequences when transformed into plant tissue.

The term "expression" as used herein is intended to describe the transcription and/or coding of the sequence for the gene product. In the expression, a DNA chain coding for the sequence of gene product is first transcribed to a complementary RNA, which is often an mRNA, and then the thus transcribed mRNA is translated into the above mentioned gene product if the gene product is a protein. However, expression also includes the transcription of DNA inserted in antisense orientation to its regulatory elements. Expression, which is constitutive and possibly further enhanced by an externally controlled promoter fragment

thereby producing multiple copies of mRNA and large quantities of the selected gene product, may also include overproduction of a gene product.

The term "translation start codon" or "initiation codon" refers to a unit of three nucleotides (codon) in a nucleic acid sequence that specifies the initiation of protein synthesis.

The term "signal peptide" refers to the N-terminal extension of a polypeptide which is translated in conjunction with the polypeptide, forming a precursor protein and which is required for its entry into the secretory pathway. The signal peptide may be recognised by the mechanisms within the same species or unrelated species plants, necessary for direction of the peptide into the secretory pathway. The signal peptide may be active in roots, seeds, leaves, tubers and other tissues of the plant. The term "signal sequence" refers to a nucleotide sequence that encodes a signal peptide. The term "ER targeting signal" refers to the N-terminal extension of a polypeptide, which is translated in conjunction with the polypeptide forming a precursor protein and which is required for its entrance into the Endoplasmic Reticulum (ER) of a cell. The ER targeting signal may be recognised by the mechanisms within the same species or unrelated species plants, necessary for direction of the peptide into the ER and/or the vacuole of a cell. ER targeting signals may be active in roots, seeds, leaves, tubers and other tissues of the plant. The term "ER targeting sequence" refers to a nucleotide sequence that encodes the ER targeting signal.

A "tissue specific promoter" refers to a sequence of DNA that provides recognition signals for RNA polymerase and/or other factors required for transcription to begin, and/or for controlling expression of the coding sequence precisely within certain

tissues or within certain cells of that tissue. Expression in a tissue specific manner may be only in individual tissues, or cells within tissues, or in combinations of tissues. Examples may include tissue specific expression in roots only and no other tissues within the plant, or may be in leaves, petals, ovules and stamen, and no other tissues of the plant. Here, "tissue specific" is also meant to describe an expression in a particular tissue or cell according to which the expression takes place mainly, but not exclusively, in the tissue. Such an expression is also termed "tissue abundant".

"Selective expression" refers to expression mainly, preferably almost exclusively, in specific organs of the plant, including, but not limited to, roots, leaves, tubers or seed. The term may also refer to expression at specific developmental stages in an organ, such as in early or late embryogenesis or in seedlings. In addition, "selective expression" may refer to expression in specific subcellular locations within the cell, such as the cytosol or vacuole.

The term "root specific nucleic acid sequence" refers to nucleic acid sequences, i.e. genes, coding sequences and/or regulatory elements which are exclusively or mainly active in roots of plants, in particular those which direct or contribute to a root abundant or root selective expression of a protein. The term "root abundant nucleic acid sequence" refers to nucleic acid sequences, i.e. genes, coding sequences and/or regulatory elements which are mainly active in roots of plants, in particular those which direct or contribute to a root abundant or root selective expression of a protein.

The present invention also relates to a vector comprising the nucleic acid sequences according to the above, in particular to a bacterial vector, such as a plasmid, or a virus.

In a particularly preferred embodiment of the present invention the nucleic acid sequences, i.e. the 5' and/or 3' regulatory elements of the present invention contained in the vector, are operably linked to a gene of interest which in this context may also be only its coding sequence, which may be a heterologous or autologous gene or coding sequence. Such a gene of interest may be a gene, in particular its coding sequence, conferring, for instance, disease resistance; drought resistance; insect resistance; herbicide resistance; immunity; an improved intake of nutrients, minerals or water from the soil; or a modified metabolism in the plant, particularly its roots. Such a modified metabolism may relate to a preferred accumulation of useful substances in roots, for instance sugars or, vice versa, in the depletion of substances undesirable in roots, for instance certain amino acids. Thus, in the context of the present invention, a gene of interest may confer resistance to infection by a virus, such as a gene encoding the capsid protein of the BWYV or the BNYVV virus, a gene conferring resistance to herbicides such as Basta®, or to an insecticide, a gene conferring resistance to the corn rootworm, a gene encoding the toxic crystal protein of *Bacillus thuringiensis* or a gene whose expression confers male sterility. A gene of interest includes also a coding sequence cloned in antisense orientation to the regulatory sequences directing its expression. Such a construct may be used specifically to repress the activity of undesirable genes in plant cells, in particular in roots, most preferably in primary, lateral seminal and/or crown roots. The gene of interest may also comprise signal sequences, in particular ER targeting sequences,

directing the encoded protein in the ER and eventually for instance in the cell wall, vascular tissue and /or the vacuole.

In a particularly preferred embodiment the vector defined above is comprised of further regulatory elements directing or enhancing expression of the gene of interest such as 5', 3' or 5' and 3' regulatory elements known in the art, for instance enhancers such as the 35S-enhancer. Regulatory elements considered in the present invention also encompass introns or parts of introns inserted within or outside the gene of interest.

In a particularly preferred embodiment of the present invention the 3' regulatory element is a transcription termination region, preferably a poly A addition or polyadenylation sequence, most preferably the poly A addition sequence of the NOS gene of *Agrobacterium tumefaciens*.

Thus, the nucleic acid sequences of the present invention are useful since they enable the root specific expression of genes of interest in plants, in particular monocotyledonous plants. Accordingly, plants are enabled to produce useful products in their roots. The nucleic acid sequences of the present invention may also be useful to regulate the expression of genes of interest depending upon the developmental stage of the transferred cell or tissue. Furthermore, the present invention allows the specific modification of the metabolism in roots.

In a particularly preferred embodiment of the present invention the vector furthermore contains T-DNA, in particular the left, the right or both T-DNA borders derived from *Agrobacterium tumefaciens*. Of course, sequences derived from *Agrobacterium rhizogenes* may also be used. The use of T-DNA sequences in the vector of the present invention enables the *Agrobacterium tumefaciens*

faciens mediated transformation of cells. In a preferred embodiment of the present invention, the nucleic acid sequence of the present invention, together with the gene of interest and - optionally - further operably linked regulatory sequences, is inserted within the T-DNA or adjacent to it.

The present invention also relates to a non-biological, technical method of genetically modifying a cell by transforming it with a vector or a nucleic acid sequence according to the above, whereby the gene of interest operably linked to the nucleic acid sequence or sequences of the present invention is expressible in the cell. In particular, the cell being transformed by the method of the present invention is a plant, bacterial or yeast cell. In a particularly preferred embodiment of the present invention, the above method further comprises the regeneration of the transformed cell to a differentiated and, in a preferred embodiment, fertile plant.

The method to transform a cell with a vector according to the present invention may be any method known to effectively transfer nucleic acid sequences into a host cell, thereby allowing its expression therein and eventually the regeneration of the cell to a plant. In a particularly preferred embodiment of the present invention, the transfer of the nucleic acid sequence may be mediated by *Agrobacterium tumefaciens* or *rhizogenes*. However, any other method known to eventually achieve the same results may be used, such as direct uptake of nucleic acid sequences, microinjection of nucleic acid sequences, or particle bombardment.

The present invention also relates to host cells transformed with the vector of the present invention, in particular plant, yeast or bacterial cells, in particular monocotyledonous or di-

cotyledonous plant cells. The present invention also relates to cell cultures, tissue, calluses, etc. comprising a cell according to the above, i.e. a transgenic cell.

Furthermore, the present invention relates to plants, harvest and propagation material, parts of plants, plant tissue, plant seeds, plant leaves, plant roots, leaves, or embryos containing a host cell of the present invention. These plants, plant tissues, plant seeds and plant parts are also called "transgenic". These plants or plant parts are characterised by, as a minimum, the presence of the transferred nucleic acid sequence of the present invention in their genome or, in cases where the nucleic acid sequences are autologous to the transferred host cell, are characterised by additional copies of the nucleic acid sequences of the present invention. Preferably, the nucleic acid sequences of the present invention are linked to genes of interest or antisense DNA normally not found in the transferred cell operably linked to the nucleic acid sequence of the present invention, at least not in that order or orientation.

Thus, the present invention also relates to roots, leaves, calluses, plant tissue, tassels, etc., nonbiologically transformed, which possess, stably integrated in the genome of their cells, a heterologous or autologous nucleic acid sequence containing a regulatory element of the present invention recognised by the polymerases of the cells of said plant parts and the gene of interest encoding a protein of interest or being an antisense construct.

Thus, the invention relates to plants, nonbiologically transformed, which possess, stably integrated in the genome of their cells, a heterologous or autologous nucleic acid sequence containing a regulatory element of the present invention recognised

- 18 -

by the polymerases of the cells of said plants and a gene of interest encoding a protein of interest or being an antisense construct.

The teaching of the present invention is therefore applicable to any plant, plant genus, or plant species wherein the regulatory element of the present invention is recognised by the polymerases of the cells.

Finally, the present invention relates to a method for isolating or cloning a root specific gene and/or root specific regulatory elements, such as promoters whereby a nucleic acid sequence of the present invention is used to screen nucleic acid sequences derived from any source, such as genomic or cDNA libraries derived from plants, in particular monocotyledonous plants. The nucleic acid sequences of the present invention thereby provide a means of isolating related regulatory sequences of other plant species which confer root specificity to genes of interest operably linked to them.

Further preferred embodiments of the present invention are mentioned in the claims.

The invention may be more fully understood from the following detailed sequence descriptions which are part of the present teaching. The SEQ ID Nos. 1 to 15 are incorporated in the present invention. The positions indicated below refer to the sequence numbering of SEQ ID No. 14.

SEQ ID No. 1 is a partial DNA sequence of the zmGRP3 (glycine-rich protein: GRP) gene of Zea mays. The 1760 bp (base pair) sequence spans the region from and including position 1760 towards the 5' end, up to and including position 1.

SEQ ID No. 2 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 1348 bp sequence spans the region from and including position 1760 towards the 5' end, up to and including position 413.

SEQ ID No. 3 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 1096 bp sequence spans the region from and including position 1760 towards the 5' end, up to and including position 665.

SEQ ID No. 4 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 746 bp sequence spans the region from and including position 1760 towards the 5' end, up to and including position 1015.

SEQ ID No. 5 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 554 bp sequence spans the region from and including position 1760 towards the 5' end, up to and including position 1207.

SEQ ID No. 6 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 406 bp sequence spans the region from and including position 1760 towards the 5' end, up to and including position 1355.

SEQ ID No. 7 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 190 bp sequence spans the region from and including position 1760 towards the 5' end, up to and including position 1571.

SEQ ID No. 8 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 1354 bp sequence spans the region from and including

position 1354 towards the 5' end, up to and including position 1.

SEQ ID No. 9 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 1497 bp sequence spans the region from and including position 1497 towards the 5' end, up to and including position 1.

SEQ ID No. 10 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 1550 bp sequence spans the region from and including position 1550 towards the 5' end, up to and including position 1.

SEQ ID No. 11 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 1710 bp sequence spans the region from and including position 1710 towards the 5' end, up to and including position 1.

SEQ ID No. 12 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 856 bp sequence spans the region from and excluding the translation stop codon at position 2558 - 2560 towards the 3' end up to position 3416.

SEQ ID No. 13 is a partial DNA sequence of the zmGRP3 gene of Zea mays. The 440 bp sequence spans the region from and excluding the translation stop codon towards the 3' end up to position 3000.

SEQ ID No. 14 is a large part of the genomic DNA sequence of the zmGRP3 gene of Zea mays comprising 3416 nucleotides and encompassing the coding region of the gene, a sequence of 20 bp between and excluding the translation initiation codon ATG (position 1781 - 1783) and the nucleotides CCA at position 1758

- 1760 and the regulatory elements identified in SEQ ID Nos. 1 to 13.

SEQ ID No. 15 is a partial DNA sequence of the zmGRP3 gene of *Zea mays*. The 1074 bp sequence spans the region from and excluding the most 3' located base "C" at position 3416 of SEQ ID No. 14 to the sequence motif "TCC" at position 4488-4490. Thus, the complete genomic DNA sequence of zmGRP3 comprises 4490 bp.

The invention is further illustrated by way of example and the following drawings.

Figure 1 shows a restriction map of the genomic clone zmGRP3 described in SEQ ID No. 14.

Figure 2 shows restriction maps of 5' deletion constructs of the present promoter element corresponding to SEQ ID Nos. 1 to 7.

Figure 3 shows restriction maps of 3' deletion constructs of the present promoter element corresponding to SEQ ID Nos. 8 to 11.

Figure 4 shows a northern blot analysis for various tissues of *Zea mays*.

Figure 5 depicts DNA constructs used for transient expression experiments.

Example 1: Cloning of the genomic zmGRP3 sequence

The genomic clone zmGRP3 was isolated by differential screening of a cDNA library made from maize coleoptile nodes, subsequent

- 22 -

isolation of a specific root specific cDNA and isolation of the corresponding genomic clone.

A cDNA library from maize coleoptilar nodes with emerging developing young crown roots was made by choosing 7-9 days old wild-type maize seedlings. mRNA from 30-40 of the wild-type coleoptilar nodes (about 15 mg per piece of tissue) was isolated with oligo(dT)-cellulose using the "Quick prep mRNA purification kit" (Pharmacia, Freiburg). Double stranded cDNA was prepared using the "Time Safer"-cDNA synthesis kit of Pharmacia Freiburg. After elimination of cDNAs with a size less than 0.4 kb (kilobases) the cDNAs were ligated into the phage vector λ -ZAP-II (Stratagene) using the ligation kit "Gig-Pack-Gold" (Stratagene, Heidelberg). The phages were plated on E. coli strain XL 1B. The obtained library had a titre of 3.7×10^6 pfu/ml. The inserts had an average size of 1.4 kb. The phages of the cDNA library were plated out in low density (about 1000-2000 pfu per agar plate (12 x 12 cm)). Per plate two nitrocellulose filters as replicas were prepared. Both filters were then separately hybridized, each with a different probe.

As probes radioactively labelled first strand cDNAs of mRNA were used which a) were derived from the coleoptilar nodes of wild-type seedlings (with formation of crown roots) and b) derived from coleoptilar nodes of rt-cs mutant seedlings (without formation of crown roots) (Hetz, et al. Plant Cell, 1996. Pp. 10, 845-857). The first strand cDNA was labelled using radioactivity and, for further analysis, digoxigenin.

Radioactive Labelling of first strand cDNA:

Materials:

ca. 1-3 μ g mRNA

5x RT-Buffer

250 mM Tris/HCl pH 8.5

- 23 -

	40 mM MgCl ₂
	150 mM DTT
dNTP-Mix	dTTP, dGTP, dATP, ea 5 mM
	dCTP 1.3 mM
Random primer (0.8 µg/µl)	
RNase-Inhibitor (30 U/µl)	
32P-dCTP (10 µ Ci/µl)	
SuperScript Reverse Transcriptase (Gibco, 100 U/µl)	

For standard labelling 1-3 µg of mRNA were dissolved in 25.5 µl of H₂O, denaturated for 10 minutes at 65°C, then cooled in ice water. The following agents were added in order: 10 µl 5 x RT-Buffer, 1 µl of Rnasin, 2.5 µl of dNTP-Mix, 5 µl of random primer, 5 µl (=50 µCi) ³²P-dCTP, and 1 µl of SuperScript Reverse Transcriptase. The preparation was mixed thoroughly and incubated for 2 hours at 42°C. A final purification was done using the "Nucleotide Removal Kit" (Quiagen, Hilden).

Plaques giving a signal on the filter hybridized with the wild-type probe, but not giving a signal on the filter hybridized with rt-cs probe were excised and analysed. An in vivo excision was carried out and the cDNA insert was cloned into plasmid pBluescript. Altogether, 32 plaques were excised and analysed. For the further analysis, the isolated plasmid DNA clone was labelled with digoxigenin and hybridized in a northern blot analysis against 10 µg total RNA from wild-type and mutant coleoptilar nodes.

The labelling with digoxigenin of first strand-cDNA was done as follows:

Materials:

ca. 1-3 µg mRNA

5x RT-Buffer

250 mM Tris/HCl pH 8.5

- 24 -

40 mM MgCl₂
150 mM DTT
dNTP-Mix dCTP, dGTP, dATP, ea 5 mM
 dTTP 1.3 mM
RNase-Inhibitor (Fermentas, 30 U/ μ l)
SuperScript Reverse Transcriptase (Gibco, 100 U/ μ l)
Digoxigenin dUTP (Boehringer)
Oligo dT (0.6 μ g/ μ l)
EDTA solution (0.2 M)
LiCl solution (4 M)
EtOH (100%, 70%)

The mRNA was denaturated for 5 minutes in 23.4 μ l of H₂O at 65°C, then rapidly cooled in ice water. The following agents were added in order: 10 μ l 5x RT-Buffer, 1 μ l of RNase-Inhibitor (ca. 20 units), 5 μ l of oligo-dT (final concentration 0.06 μ g/ μ l) 3.6 μ l of DIG-dUTP (final concentration 0.13 mM), 5 μ l of dNTP-mix and 2 μ l of SuperScript Reverse Transcriptase. The preparation was then incubated for 2 hours at 42°C. The labelled first strand cDNA was precipitated by adding of 2 μ l of EDTA solution, 5 μ l of LiCl solution and 130 μ l of 100% EtOH. Following a washing with 70% EtOH, the cDNA resuspended in 50 μ l of H₂O and stored at -20°C.

The northern analysis showed that the clone isolated hybridized with wild-type total RNA, but not with the mutant total RNA. As the mutant tissue differed from the wild-type tissue in the absence of crown roots, the expression of the isolated clone could be related to the formation of crown roots in maize seedlings. According to northern blot analysis, the clone was expressed exclusively in the cells of roots of young maize seedlings, in particular in the tissue. The clone was used to isolate a full-length cDNA clone. The full-length cDNA clone (zmGPR3 cDNA) was

in turn used to isolate a genomic clone zmGRP3 which is partially described in SEQ ID No. 14 as follows:

The sequence given in SEQ ID No. 14 comprises the 5' regulatory elements of the present invention, the coding region of the maize zmGRP3 gene and the 3' regulatory elements of the present invention except the most distal part of the 3' region which, however, is given in SEQ ID No. 15. The coding region of zmGRP3 spans from the translation initiation codon at position 1781 to 1783 to the translation termination signal TGA at 2558 to 2560. The 5' regulatory element of the present invention comprises at position 1712 up to 1719 the putative TATA-box "tataaata".

The sequences depicted in SEQ ID Nos. 1 to 7 comprise the putative TATA-box and are particularly useful for the purposes described in the present invention.

The 3' regulatory element of the present invention, in particular the elements described in SEQ ID No. 12 and 13 comprise at position 2957 the polyadenylation signal. The 3' regulatory element located 3' to SEQ ID No. 12 and 13 and depicted in SEQ ID No. 15 may prove particularly useful as expression enhancing element.

The coding sequence of zmGRP3 codes for a glycin-rich protein, whose transcripts accumulate exclusively in roots of young maize seedlings following developmentally specific patterns. The protein exhibits a hydrophobic domain at the N-terminal region followed by repeated glycin-rich motifs. The hydrophobic domain at the N-terminal region is believed to be part of an ER-type signal peptide. The obtained genomic clone is the first nucleic acid sequence encoding a glycin-rich protein expressed exclusively in the root system, in particular that of maize.

Example 2: Northern analysis

As the tissues to be compared, i.e. wild-type and mutant tissues differed only in the presence or absence of crown roots, the transcription of *zmGRP3* mRNA could be identified to be closely connected with the formation of crown roots. However, to determine whether the *zmGRP3* transcription could also be detected in other tissues or other types of roots, primary roots, lateral seminal roots, and lateral roots (of maize) the following northern analysis was carried out. mRNA was isolated from various organs such as kernels, shoot meristems, leaves, coleoptilar nodes, tassels, various zones of primary, lateral, seminal and crown roots and root tips of lateral roots. The mRNA was then on a gel and hybridized with the *zmGRP3* cDNA isolated above.

Figure 4 A to D illustrate the detection of *zmGRP3* transcripts in northern analysis. After electrophoretic separation and blotting, the RNAs (10 μ g) were hybridized with the DIG-labelled *zmGRP3* cDNA. Total RNAs were isolated from; Fig. 4A, coleoptilar node with emerging young crown roots (lane 1), shoot meristem (lane 2), root tips of crown roots (lane 3), of primary roots (lane 4), or of lateral seminal roots (lane 5), leaves (lane 6), kernel (12-14 days after pollination, lane 7), or tassel (lane 8). Fig. 4B, C and D represent RNA samples taken from defined root segments of crown roots (B), of primary roots (C), or of lateral seminal roots (D): root tip up to cm 1 (lane 1), cm 2 (lane 2), cm 3 (lane 3), and cm 4 (lane 4). Lane 5 in C represents root tips (up to 1 cm) of secondary roots. The lower parts of A, B, C and D show the ethidium bromide stained gels displaying the 18S and 26S rRNA bands.

Figure 4B indicates that *zmGRP3* mRNA accumulation is developmentally and spatially regulated within the root with the highest

- 27 -

level of accumulation occurring in the meristematic and elongation region (cm 1), low levels in early regions of cell maturation (cm2) and again increasing levels in later regions of cell maturation (cm 3 and 4) (cm sections as defined in Held et al, Plant Physiol. (1993) pp. 102, 1001-1008). In crown roots the zmGRP3 mRNA is predominantly expressed in the root tip. A weak hybridization signal is detected in the later stage of root development (cm 4). A possible explanation for this difference in accumulation between crown roots and primary/lateral seminal roots is that the development of primary and lateral seminal roots begins 4 to 5 days before crown roots. The transcript was surprisingly not detected in tips of lateral roots.

Example 3: Preparation of transgenic plants

Materials and Methods:

Isolation and culture of immature embryos for particle bombardment

Immature maize embryos (crosses between inbred line A188 and H99) with a size of 1.0-1.5 mm were isolated under sterile conditions. They were cultured with the scutellar side facing upward on modified N6-Medium (D'Halluin et al. 1993) with 1 mg/l 2,4-D, solidified with 0.8% agarose or 0.3% phytigel.

The explants were bombarded 4 to 12 days after isolation. For the osmotic pre-treatment, the embryos were placed with the scutellar side facing upward on MSC-medium (Zhong et al. 1992) in which a higher osmotic value was adjusted with sucrose to 670 mOsm/kg. The osmotic treatment was started 4 h before bombardment and was continued for 20 to 24 h after bombardment. In ex-

periments where the rhizobial part of the embryo was bombarded, the embryo was cut immediately or one day after isolation.

Particle bombardment

Particle acceleration was performed with the PDS 1000/He gun (BioRad, Munich, Germany). Five µg plasmid DNA was precipitated onto gold particles with an average size of 0.4-1.2 µm (Heraeus, Karlsruhe, Germany) following a protocol described by BioRad (Munich, Germany) and modified according to Becker et al. (1994). For stable transformation experiments, the particle-DNA pellet was resuspended in 240 µl ethanol. For each bombardment, 3.5 µl were spread on the macrocarrier.

Parameters used for particle bombardment

Distance between

A: rupture disk and macrocarrier	2.5 cm
B: macrocarrier and stopping screen	0.8 cm
C: stopping screen and target cells	5.5 cm
Gas pressure	1350 psi
Partial vacuum	28 inch Hg
Particles	gold (size: 0.4-1.2 µm)
Amount of particles	30 µg per shot

Constructs

In experiments for stable transformation, the p35Spat gene (Brettschneider et al., 1997) was used as selection marker gene. In co-transformation experiments 2.5 µg DNA of the plasmid with the selection marker gene was mixed with the second plasmid containing the promoter-reporter gene and precipitated together onto the particles. The promoter used for transient and stable

transformation experiments has the sequence depicted in SEQ ID No. 1 and was fused to a GUS reporter gene. Further deletion constructs in the promoter region were made which are depicted in Fig. 2 and 3.

Figure 2 depicts 5' deletion constructs (Fig. 2 (b)) of the full length promoter of SEQ ID No. 1 (Fig. 2(a)), while Figure 3 shows 3' deletion constructs (Fig. 3 (b)) of the full length promoter of SEQ ID No. 1 (Fig. 3 (a)).

In detail, Figure 2a is a schematic representation of the cloned promoter fragment of *zmGRP3*. The positions of the restriction sites of the following restriction enzymes are presented (the numbers denote the nucleotide positions of the restriction sites in the promoter fragment): X: *Xho*I (1), G: *Bgl* II (1206), V: *Pvu*I (120), K: *Kpn*I (1354), P: *Pst*I (588), N: *Bst*NI (572, 1760), S: *Sac*I (664), B: *Bam*HI (698, 1014), Z: *Bst*XI (412), C: *Cl*aI (1497, 1525, 1570), D: *Dra*I (906), Y: *Xba*I (963). Furthermore, the position of the putative TATA box is indicated.

Figure 2b gives an overview of the 5' promoter deletion clones prepared. Presented is in each case the length of the promoter fragment still present (boldface), as well as the size of the region deleted from the 5' end (in brackets) of the promoter. The fragments were cloned in a vector that contained the β -glucuronidase gene (*uid A*).

Figure 3a) is a schematic representation of the cloned promoter fragment of *zmGRP3*. The positions of the restriction sites of restriction enzymes are presented as in Fig. 2a.

Figure 3b) is an overview of the 3' promoter deletion clones prepared. Presented is in each case the length of the promoter

fragment still present (boldface), as well as the size of the region deleted from the 3' end (in brackets) of the promoter. The fragments were cloned in a vector that contained the β -Glucuronidase Gen (uid A) downstream from the -46bp-region of the CaMV 35S promoter (with TATA box). Thus, these 3' deletion constructs contain the CaMV 35S promoter initiation site.

Expression studies

For transient expression studies, different maize tissues, i.e. roots, leaves of seedlings, germinating embryos, were bombarded with the promoter constructs identified above. For histochemical GUS-detection, the bombarded tissues were incubated one day after bombardment at 37°C for 20 h in X-gluc staining solution (McCabe *et al.* 1988). After staining leaf tissues with x-gluc chlorophyll was extracted in ethanol/acetic acid glacial (3:1) for 30 to 60 min at 65°C and washed once with 70% ethanol.

For quantification of the promoter strength, bombarded tissues were analysed in a protein GUS-assay (Jefferson *et al.* 1987). For standardisation of the transformation frequency, the promoter constructs were co-transformed with a luciferase reporter gene under control of the actin promoter from maize (positive control). As negative control, pUC 19 DNA was used in the same amount as the promoter constructs. One day after bombardment, proteins of the bombarded tissue were extracted and analysed for GUS and LUC activity. The analysed root tissue exhibited GUS and LUC activity, while the other bombarded tissues only showed LUC activity. These results clearly evidence root specificity of the promoter element of the present invention.

The table I below shows the results of the transformation of 5' deletion constructs.

Promoter	Root	Leaf	Embryo
SEQ ID No. 1, 0	+	-	-
SEQ ID No. 2, -412	+	-	-
SEQ ID No. 3, -664	+	-	-
SEQ ID No. 4, -1014	+	-	-
SEQ ID No. 5, -1206	+	-	-
SEQ ID No. 6, -1354	+	-	-
SEQ ID No. 7, -1570	+	-	-
negative control	-	-	-
positive control	+	+	+

Table I: Transformation of various maize tissues with 5' deletion promoter constructs.

All of the tested promoter constructs clearly and unambiguously show expression in roots, but not in leaves or in the embryo. Even the smallest promoter fragment (SEQ ID No 7, 190 bp length) shows significant expression exclusively in the root.

Figure 5 shows further gus-fusion constructs using the regulatory elements of the present invention (not to scale). The boxes marked "GUS" symbolise the coding region of the uidA gene from E. coli, the position of the start and stop codons is indicated in each case. The 35S promoter from pBI121 was deleted in the constructs produced (pBI121-35S) or replaced by the GRP3-promoter (pBI-GRP3-Prom, pBI121-GRP3-Prom-3') or the GRP3-promoter + 2x35S-Enhancer (pBI121-2x35S-En-GRP3-Prom-3'). In some cases moreover the 3' region of GRP3 (pBI121-GRP3-Prom-3', pBI121-2x35S-En-GRP-Prom-3') was inserted instead of the NOS-terminator. The positions of restriction endonuclease-sites relevant to this are indicated under the relevant constructs (H:

- 32 -

HindIII, L: Sal/I, X: XbaI, B: BamHI, M: SmaI, S: SacI, E: EcoRI).

Figure 5 thus shows further gus-fusions constructs using the regulatory elements of the present invention. PBI 121 is a positive control while PBI-121-35S is a negative control. PBI-121-GRP3-Prom is a construct using the promoter of SEQ ID No. 1 being functionally linked to a gus-reporter gene and the NOS-terminator. PBI-121-GRP3-Prom 3' is a DNA construct of the present invention using the promoter element of SEQ ID No. 1 functionally linked to the gus-reporter gene and a 3' regulatory element of the present invention having the sequence of SEQ ID No. 12 and added 3' thereto of SEQ ID No. 15. Therefore the 3' regulatory element spans the region from and excluding the translation stop codon at position 2558-2560 towards the 3' end up to position 4490. This 3' regulatory element being the combination of SEQ ID No. 12 and SEQ ID No. 15 has also been used in DNA construct PBI-121-2 X 35S-EN-GRP3-Prom-3' which is similar to the above described construct but additionally has the 2 X 35S-enhancer (nucleotide positions 7089 to 7357 and -346 to -78 of the CaMV virus genome relative to the start of transcription described in Fang et al. (1989) and Franck et al. (1980); data base accession No. V00141 Y 02048 VRL 12. Sept. 1993; NID: g 58821).

The following table II shows the expression results in transient essays in roots and leaves. Accordingly, it can be shown that both the 5' and 3' regulatory elements of the present invention contribute to tissue specific expression in roots indicating that DNA constructs using both the 5' and 3' elements of the present invention or the elements separately may prove useful in genetic engineering of plants.

Table II: Transient expression studies

Construct	Activity in the Transient Assay in Roots	Activity in the Transient Assay in Leaves
pBI121	+++++	+++++
pBI121-35S	-	-
pBI121-GRP3-Prom	+	-
pBI121-GRP3-Prom-3'	++	-
pBI121-2x35S-En-GRP3-Prom-3'	+++	-

(+: strong expression, degree indicated by number of "+", -: no or hardly any expression).

Explants were cultured after bombardment for two weeks on N6 1-100-25 medium at 26°C in the dark. Selection was started 14 days after bombardment when the explants were subcultured on N6 1-100-25 medium without casaminoacids supplemented with 5 mg/l phosphinotricin (PPT), the active compound of the commercial herbicide Basta®. After two weeks, the calli were subcultured for another two weeks on N6 1-100-25 medium with 5 mg/ l Basta®. For regeneration, embryogenic calli were transferred on hormonefree MS-medium with 1 mg/l PPT and cultured at 24°C under light (16 h).

Green shoots were transferred to Magenta boxes with half-strength MS-medium and 1 mg/l PPT solidified with 0.3 % phytagel. Plantlets with a height of 6-8 cm which survived selection were transferred into soil after they generated roots.

Small plants were cultured in soil in the greenhouse for 1 week under a plastic or glass lid. Routinely, more than 90% of the regenerants survived the transfer into soil. To confirm the selection, surviving plants were sprayed once or twice with a Basta®-solution containing 250 mg/l PPT and 0.1% Tween.

Transformants were verified by southern analysis

DNA isolation and Southern blot hybridisation

For the analysis of stable transformants, total genomic DNA was isolated from primary transformants and their progeny using the protocol of Dellaporta et al (1983). 10 or 15 µg of DNA, uncut or digested with restriction enzymes were separated by electrophoresis and transferred to a Hybond N membrane (Amersham/England) or a BiodyneA membrane (Pall/England). Introduced DNA of the present invention (SEQ ID No. 1) was detected using a modified protocol of the non-radioactive digoxigenin chemiluminescent method (Neuhaus-Url et al. 1993). Filters were hybridised with PCR-labelled Dig probes. Stably transformed transgenic maize plants could be obtained.

Example 4

In situ hybridization experiments of various types of maize roots with zmGRP

Method:

In situ hybridisation experiments were carried out according to a modified protocol from Coen et al., 1990 (Cell 63, 1311-1322). First the tissue to be analysed was fixed in 4% paraformaldehyde over night. The tissue then was dehydrated in an increasing concentration of ethanol and finally embedded in paraffin.

The tissue was cut in 8-12µm slices. After that the slices were hybridised with DIG labelled zmGRP3 RNA sense or antisense probes which had been hydrolytically digested to a size of about 200 bp. Hybridisation was carried out in 50% formamid at a tem-

perature of 50°C. Washing and the immunological staining was carried out exactly as described by Coen et al., 1990.

Results:

Longitudinal sections of different 5 day old root types were used. These slices were derived from primary root as well as from lateral crown roots and from stem derived crown roots. The embryogenic primary root as well as lateral and stem derived crown roots showed the same hybridisation pattern. In all cases there was no signal with the sense probe, whereas with the antisense probe there was a strictly root specific hybridisation. This hybridisation was cell specifically and was restricted to the epidermal cell layer and cells of the columella root cap. In all other tissue types there was no hybridisation signal.

References

- Becker, D., Brettschneider, R. and Lörz, H. (1994) Fertile transgenic wheat from microprojectile bombardment of scutellar tissue. *The Plant Journal* 5, 299-307.
- Brettschneider et al (1997) Efficient transformation of scutella tissue of immature maize embryos. *Theoretical Applied Genetics* (94), 337.
- Coen et al., 1990 (*Cell* 63, 1311-1322).
- Dellaporta, S.L., Wood, J. and Hicks, J.B. (1983) A plant DNA miniprep: Version II *Plant Mol. Biol. Rep.* 4, 419-21.
- D'Halluin, K., Bonne, E., Bossut, M., De Beuckeleer, M. and Lee-mans, J. (1993) Transgenic maize plants by tissue electroporation. *The Plant Cell* 4, 1495-1505.
- Fang et al., (1989) *Plant Cell* 1, 141-150
- Franck et al., (1989) *Cell* 21 (1), 285-294

- McCabe, D.E., Swain, W.F., Martinelli, B.J. and Christou, P. (1988) Stable transformation of Soybean (*Glycine max*) by particle acceleration. *Bio/Technology* 6, 923-926.
- McElroy, D., Zhang, W., Cao, J. and Wu, R. (1990) Isolation of an efficient Actin promoter for use in rice transformation. *The Plant Cell* 2, 163-171.
- Neuhaus-Url, G. and Neuhaus, G. (1993) The use of the non-radioactive dioxigenin chemiluminescent technology for plant genomic Southern blot hybridisation: a comparison with radioactivity. *Transgenic Research* 2, 115-120.
- Zhong, H., Srinivasan, C. and Sticklen, M.B. (1992) In-vitro morphogenesis of corn (*Zea mays* L.) *Planta* 187, 483-489.

Claims

1. A nucleic acid sequence for use in cloning and expressing a root specific nucleic acid sequence in a plant which is selected from the group consisting of
 - a) the nucleic acid sequence set out in SEQ ID No. 1 or a complementary strand or part thereof
 - b) a nucleic acid sequence which hybridizes to the nucleic acid sequence defined in (a) or a complementary strand thereof and
 - c) alleles or derivatives of the nucleic acid sequence defined in (a) or (b).
2. The nucleic acid sequence of claim 1 which is selected from the group consisting of
 - a) the nucleic acid sequence set out in SEQ ID No. 2 or a complementary strand or part thereof.
 - b) a nucleic acid sequence which hybridizes to the nucleic acid sequence defined in (a) or a complementary strand thereof and
 - c) alleles or derivatives of the nucleic acid sequences defined in (a) or (b).

-38-

3. The nucleic acid sequence according to claim 1 or 2, which is selected from the group consisting of
 - a) the nucleic acid sequence set out in any one of SEQ ID No. 3 to 11 or a complementary strand or part thereof,
 - b) a nucleic acid sequence which hybridizes to the nucleic acid sequence defined in (a) or a complementary strand thereof and
 - c) alleles or derivatives of the nucleic acid sequence defined in (a) or (b).
4. A nucleic acid sequence for use in cloning and expressing a root specific gene in a plant which is selected from the group consisting of
 - a) the nucleic acid sequence set out in any one of SEQ ID No. 12 to 15 or a complementary strand or part thereof,
 - b) a nucleic acid sequence which hybridizes to the nucleic acid sequences defined in (a) or a complementary strand thereof and
 - c) alleles or derivatives of the nucleic acid sequence defined in (a) or (b).
5. The nucleic acid sequence of any one of the preceding claims, which is derived from maize.
6. A vector comprising the nucleic acid sequence of any one of the preceding claims.

-39-

7. The vector of claim 7, which is a bacterial or viral vector.
8. The vector of any one of claims 6 or 7, wherein the nucleic acid sequence of any one of claims 1 to 5 is operably linked to a gene of interest.
9. The vector of claim 9, wherein the gene of interest is chosen from a gene which confers a character of agronomic or industrial benefit, for example a gene for resistance to infection by a virus, a gene conferring resistance to a herbicide or to an insecticide or, alternatively, a gene whose expression confers male sterility.
10. The vector of any one of claims 6 to 9, which comprises further regulatory elements directing or enhancing the expression of the gene of interest.
11. The vector of any one of claims 6 to 10, wherein the further regulatory elements are 5',3' or 5' and 3' elements.
12. The vector of claim 11, wherein the 3' regulatory element is the poly A addition sequence of the NOS gene of *Agrobacterium tumefaciens*.
13. The vector according to any one of claims 6 to 12, which furthermore contains T-DNA, in particular the left, the right or both T-DNA borders.

-40-

14. The vector according to claim 13, wherein the nucleic acid sequence, optionally in conjunction with the gene of interest, is located within the T-DNA or adjacent to it.
15. A host cell containing the vector of any one of claims 6 to 14.
16. The host cell of claim 15, which is a plant, yeast or bacterial cell, in particular a cell from a monocotyledonous or dicotyledonous plant.
17. A cell culture, preferably a plant cell culture comprising a cell according to any one of claims 15 to 16.
18. A plant comprising a host cell according to any one of claims 15 to 16.
19. Seeds, propagation material, harvest material and plant tissue, preferably comprising a host cell according to any one of claims 15 or 16 or derived from a plant according to claim 18.
20. A method of genetically modifying a cell by transforming a cell with a nucleic acid sequence according to any one of claims 1 to 5 or a vector according to any one of claims 6 to 14, wherein the gene of interest contained in the vector is expressible in the cell.
21. The method of claim 20, wherein the cell is a plant, bacterial or yeast cell.

-41-

22. The method of claims 20 or 21, wherein the transformed cell is regenerated into a differentiated plant.
23. The method of any one of claims 20 to 22, wherein the cell is transformed by transfer of a vector or nucleic acid sequences from a bacterium to the cell.
24. The method of any one of claims 20 to 23, wherein the cell is transformed by direct intake of a nucleic acid sequence or a vector, by microinjection or particle bombardment with a nucleic acid sequence or a vector.
25. A method for isolating a root specific gene and/or root specific regulatory element from a plant, whereby a nucleic acid sequence of any one of claims 1 to 5 or a vector of any one of claims 6 to 14 is used to screen nucleic acid sequences derived from the plant.

Fig. 1




Fig.2

Fig.2a




Fig.2b





Fig.3

Fig.3a



4/5
Fig. 4





Fig.5



-1-

SEQUENCE LISTING

<110> Agricultural Technology and Genetics GmbH

<120> Regulatory Sequences for Root Specific or Root Abundant
Gene Expression in Plants

<130> 23143 ATG

<140>

<141>

<150> EP 98117251.3

<151> 1998-09-01

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 1760

<212> DNA

<213> Zea mays

<400> 1

```

ctcgagatgt tggatagaag aggaattgcg agcaaccgag gtctccaagg cacgccaacg 60
cgcacctctg gcagtgaggt ggctcgctgat gtcgcgaagg agcttcgatt gttcgtcgat 120
cgcgagcttc agatttggtt ccatgacccc agattgtttg gcgcggcgcg tgtaatgagc 180
agacgccaga cccgagaccg gtgtctccga taccaattgt tagcaatagc agcggacaag 240
cagcgaacaa tccgagagac atagtttggt ggaggagcag atagcttgga gaggaagaag 300
aacaatagt acagcgtaga ttctctctg gtctcctctg ttaccctctc tcaatctaata 360
actcctatta caaggtcggc ccatcaggcg acccagtcgc ggttccacga acttgggatt 420
gggtttgtgc ggacgccgac tggttcttgg ctctgctgga gtcttgtctg tggagctgtt 480
gctcgcgctg ctaacaatct cttgttgttt gcgacgactt cgcgtggcca cgcgttaact 540
gcgctctgct caaagaaatt gcctatacag tgcttggcgt cagctgcagg cgttgaatcc 600
gaggtcgcga gtacgaggca aacgctgagc tgcatgctgt accggttta ttaataactg 660
agctctactc gctacgttag ctataggcac cagaggcgga tccagagggg gggcaaagta 720
ggccatggcc cccctcaat tttgtacacc cttttatacc taatgattat ttagtattaa 780
gtgtagaaaa aatcaaaatt ttagatagta taaaaatctt gttctaaatc tctaaaacta 840
atagctagtt gctaaaatta gccaaaaggt ttagaatgga tcaactaatt gttagctata 900
ccctttaaat aagtattaat tgtagatgg cccaacctag ctaaaaccag ttaacagtta 960
gctctagatg tttagaacat ggcctaaaca accatattat gaggctactc gccggatcct 1020
ctcggttcag tcctagcatc taccagtctg actctaactc tcccgcacac acctaaacca 1080
gtctgctcgc tgccctgttt ccgccaccga ccattcccgc atgcgacgtc acccgacttc 1140
gccccttcgt agcgcctccg tcccttgctc tgtttttctc gtgacgtcga tccgctcgac 1200
aaattagatc tcgctcgctg caacgatatg acttatcccc tgcggtcggg ggacttgacg 1260
aactagaaaa ttatggctct catgtggtct ttttggcccc tccctaaattt tcgtcctgcg 1320
tccgccactc tatagctggt ggagtgcggg gtaccgtatc gtgaatctga agtcgaacag 1380
tgatggcgta ctatctaag tcccgctcag taatatcact gttgccgacg atgggaatct 1440
ctagttttga cagaaaccaa ggcaactgct atgctagcta attaattcca gagagatcga 1500
tttctacagt gctagctgca acaatcgatg caattggcat cagacgatat atgctaattg 1560
ttttctttat cgatacgtgg tcaacagtgc gatccagatt acagagttct ctgcacctga 1620
tcggatctca tcgcacatgg acacccatct gccaacccaa cgcggggcgg ggaacccgaa 1680

```

-2-

acatcgcgtc catgcacgac cccacgcgag ctataaatac ccatgcaatg caatgcagcg 1740
 ggtcatcatc atcgactcca 1760

<210> 2
 <211> 1348
 <212> DNA
 <213> Zea mays

<400> 2
 ttgggattgg gtttgtgagg acgcccagctg gttcttggct ctgctggagt cttgtctgtg 60
 gagctgttgc tcgcgctgct aacaatctct tgttgtttgc gacgacttcg cgtggccacg 120
 cgttaactgc gctctgctca aagaaattgc ctatacagtg cctggcgctca gctgcaggcg 180
 ttgaatccga ggtcgccagt acgaggcaaa cgctgagctg catgctgtac cggttttatt 240
 aataactgag ctctactcgc tacgttagct ataggcacca gagggcgatc cagagggggg 300
 gcaaagtagg ccatggcccc ccctcaattt tgtacaccct ttataccta atgattattt 360
 agtattaagt gtagaaaaaa tcaaaatttt agatagtata aaaatcttgt tctaaatctc 420
 taaaactaat agctagtgtc taaaatttag caaaagggtt agaattggat aactaattgt 480
 tagctatacc ctttaaataa gtattaattg ttagatggcc caacctagct aaaaccagtt 540
 aacagtttag tctagatggt tagaacatgg cctaaacaac catattatga gcctactcgc 600
 cggatcctct cggttcagtc ctacgatcta ccagtctgac tctaactctc ccgacaccac 660
 ctaaaccagt ctgctcgtcg ccctgtttcc gccaccgacc cattcccgat gcgacgtcac 720
 ccgacttcgc cccttcgtag cgcctccgct ccttgcctcg ttttctcgt gacgtcgatc 780
 cgctcgacaa attagatctc gctcgtcgca acgatatgac ttatccctcg cggtcgggtg 840
 acttgacgaa ctagaaaatt atggctctca tgtggtcttt ttggccctc ctaaattttc 900
 gtctcgctgc cgccactcta tagctgcggg agtgcggggt accgtatcgt gaatctgaag 960
 tgaacagtgc atggcgtagt atctaattgc ccgtgcagta atatcactgt tgccgacgat 1020
 gggaatctct agttttgaca gaaaccaagg caactgctat gctagctaata taattccaga 1080
 gagatcgatt tctacagtgc tagctgcaac aatcgatgca attggcatca gacgatatat 1140
 gctaattggt ttctttatcg atacgtggtc aacagtgcga tccagattac agagtctctc 1200
 cgccctgata ggatctcatc gcacatggac acccatctgc caaccaacg cggggcgggg 1260
 aacccgaaac atcgcgctca tgcacgaccc ccacgcagct ataaatacc atgcaatgca 1320
 atgcagcggg tcatcatcat cgactcca 1348

<210> 3
 <211> 1096
 <212> DNA
 <213> Zea mays

<400> 3
 ctactcgcta cgttagctat aggcaccaga ggcggatcca gagggggggc aaagtagggc 60
 atggccccc ctcaattttg tacacccttt tatacctaata gattatttag tattaagtgt 120
 agaaaaaatc aaaatttttag atagtataaa aatcttggtc taaatctcta aaactaatag 180
 ctagtgtcta aaattagcca aaaggtttag aatggatcaa ctaattgtta gctataccct 240
 ttaaataagt attaatgttt agatggccca acctagctaa aaccagttaa cagtttagctc 300
 tagatgttta gaacatggcc taaacaacca tattatgagc ctactcgccg gatectctcg 360
 gttcagtcct agcatctacc agtctgactc taatcttccc gacaccacct aaaccagtct 420
 gctcgctgcc ctgtttccgc caccgaccca ttcccgatgc gacgtcaccg gacttcgccc 480
 ctctgtagcg cctcgcgtcc ttgtcctgtt tttctcgtga cgtcgatccg ctcgacaaat 540
 tagatctcgc tcgtcgcaac gatatgactt atccctcgcg gtcggtggac ttgacgaact 600
 agaaaattat ggctctcatg tggctctttt ggccctcct aaattttcgt cctgcgtccg 660
 ccactctata gctgcgggag tgcggggtag cgtatcgtga atctgaagtc gaacagtgat 720

-3-

```

ggcggtactat ctaatgtccc gtgcagtaat atcactgttg ccgacgatgg gaatctctag 780
ttttgacaga aaccaaggca actgctatgc tagctaatta attccagaga gatcgatttc 840
tacagtgcta gctgcaacaa tcgatgcaat tggcatcaga cgatatatgc taatggtttt 900
ctttatcgat acgtgggtcaa cagtgcgatc cagattacag agttctctcg ccctgatcgg 960
atctcatcgc acatggacac ccactctgcca acccaacgcg gggcggggaa cccgaaacat 1020
cgcggtccatg cagcagcccc acgcagctat aaatacccat gcaatgcaat gcagcgggtc 1080
atcatcatcg actcca                                     1096

```

<210> 4
 <211> 746
 <212> DNA
 <213> Zea mays

```

<400> 4
gatcctctcg gttcagtcct agcatctacc agtctgactc taatcttccc gacaccacct 60
aaaccagttc gctcgtgccc ctgtttccgc caccgaccca ttcccgatgc gacgtcaccc 120
gacttcgccc cttcgtagcg cctccgtccc ttgtcctggt tttctcgtga cgtcgatccg 180
ctcgacaaat tagatctcgc tcgtcgcaac gatatgactt atcccctgcg gtcgggtggac 240
ttgacgaact agaaaattat ggctctcatg tggctttttt ggccctcctt aaattttcgt 300
cctgcgtccg ccactctata gctgcgggag tgcgggggtac cgtatcgtga atctgaagtc 360
gaacagtgat ggcgtactat ctaatgtccc gtgcagtaat atcactgttg ccgacgatgg 420
gaatctctag ttttgacaga aaccaaggca actgctatgc tagctaatta attccagaga 480
gatcgatttc tacagtgcta gctgcaacaa tcgatgcaat tggcatcaga cgatatatgc 540
taatggtttt ctttatcgat acgtgggtcaa cagtgcgatc cagattacag agttctctcg 600
ccctgatcgg atctcatcgc acatggacac ccactctgcca acccaacgcg gggcggggaa 660
cccgaacat cgcggtccatg cagcagcccc acgcagctat aaatacccat gcaatgcaat 720
gcagcgggtc atcatcatcg actcca                                     746

```

<210> 5
 <211> 554
 <212> DNA
 <213> Zea mays

```

<400> 5
gatctcgctc gtcgcaacga tatgacttat cccctgcggt cgggtggactt gacgaactag 60
aaaatttatg ctctcatgtg gtcttttttg cccctcctaa attttcgtcc tgcgtccgcc 120
actctatagc tgcgggagtg cgggggtaccg tatcgtgaat ctgaagtcga acagtgatgg 180
cgtactatct aatgtcccgt gcagtaatat cactgttgcc gacgatggga atctctagtt 240
ttgacagaaa ccaaggcaac tgctatgcta gctaattaat tccagagaga tcgattttct 300
cagtgttagc tgcaacaatc gatgcaattg gcatcagacg atatatgcta atggttttct 360
ttatcgatac gtggtcaaca gtgcgatcca gattacagag ttctctcgcc ctgatcggat 420
ctcatcgcac atggacaccc atctgccaac ccaacgcggg gcggggaacc cgaaacatcg 480
cgtccatgca cgacccccac gcagctataa atacccatgc aatgcaatgc agcgggtcat 540
catcatcgac tcca                                     554

```

<210> 6
 <211> 406
 <212> DNA
 <213> Zea mays

-4-

<400> 6

```

cgtatcgtga atctgaagtc gaacagtgat ggcgtactat ctaatgtccc gtgcagtaat 60
atcactgttg ccgacgatgg gaatctctag ttttgacaga aaccaaggca actgctatgc 120
tagctaatta attccagaga gatcgatttc tacagtgcta gctgcaacaa tcgatgcaat 180
tggcatcaga cgatatatgc taatggtttt ctttatcgat acgtgggtcaa cagtgcgatc 240
cagattacag agttctctcg ccctgatcgg atctcatcgc acatggacac ccactctgcca 300
acccaacgcg gggcggggaa cccgaaacat cgcgtccatg cacgaccccc acgcagctat 360
aaatacccat gcaatgcaat gcagcgggtc atcatcatcg actcca 406

```

<210> 7

<211> 190

<212> DNA

<213> Zea mays

<400> 7

```

cgatacgtgg tcaacagtcg gatccagatt acagagttct ctgcacctga tcggatctca 60
tcgcacatgg acacccatct gccaaaccaa cgcggggcgg ggaacccgaa acatcgcgtc 120
catgcacgac cccacgcgag ctataaatac ccatgcaatg caatgcagcg ggtcatcatc 180
atcgactcca 190

```

<210> 8

<211> 1354

<212> DNA

<213> Zea mays

<400> 8

```

ctcgagatgt tggatagaag aggaattgcg agcaaccgag gtctccaagg cacgccaacg 60
cgcacacctg gcagtgaggt ggtcgctgat gtgcggaagg agcttcgatt gttcgctgat 120
cgcgagcttc agatttggtt ccatgacccc agattgtttg gcgcggcgcg tgtaatgagc 180
agacgccaga cccgagaccg gtgtctccga taccaattgt tagcaatagc agcggacaag 240
cagcgaacaa tccgagagac atagttttgg ggaggagcag atagcttgga gaggaagaag 300
aacaatagtg acagcgtaga ttctctctct gtctcctctg ttacctctc tcaatctaat 360
actcctatta caaggtcggc ccatcaggcg acccagtcgc ggttcacga acttgggatt 420
gggtttgtgc ggacgccgac tggttcttgg ctctgctgga gtcttgtctg tggagctgtt 480
gctcgcgctg ctaacaatct cttgttggtt gcgacgactt cgcgtggcca cgcgttaact 540
gcgctctgtc caaagaaatt gcctatacag tgcctggcgt cagctgcagg cgttgaatcc 600
gaggtcgcca gtacgaggca aacgctgagc tgcattgctg accggcttta ttaataactg 660
agctctactc gctacgttag ctataggcac cagaggcgga tccagagggg gggcaaagta 720
ggccatggcc cccctcaat tttgtacacc cttttatacc taatgattat ttagtattaa 780
gtgtagaaaa aatcaaaatt ttagatagta taaaaatctt gttctaaatc tctaaaacta 840
atagctagtt gctaaaatta gccaaaagg ttagaatgga tcaactaatt gttagctata 900
ccctttaaat aagtattaat tgtagatgg cccaacctag ctaaaaccag ttaacagtta 960
gctctagatg tttagaacat ggcctaaaca accatattat gagcctactc gccggatcct 1020
ctcggttcag tcttagcatc taccagtctg actctaactc tcccgacacc acctaaacca 1080
gtctgctcgc tgccctgttt ccgccaccga ccattcccg atgcgacgto acccgacttc 1140
gccccttcgt agcgctccg tcccttgctc tgttttctc gtgacgtcga tccgctcgac 1200
aaattagatc tcgctcgctc caacgatatg acttatcccc tgcggtcggt ggacttgacg 1260
aactagaaaa ttatggctct catgtggtct ttttgcccc tctaaattt tcgtcctgcg 1320
tccgccactc tatagctgcg ggagtgcggg gtac 1354

```


-5-

<210> 9
 <211> 1497
 <212> DNA
 <213> Zea mays

<400> 9
 ctcgagatgt tggatagaag aggaattgcg agcaaccgag gtctccaagg cagcccaacg 60
 cgcacccctgc gcagttaggt ggtcgctgat gtcgcgaagg agcttcgatt gttcgctgat 120
 cgcgagcttc agatttggct ccatgacccc agattgtttg gcgcggcgcg tgtaatgagc 180
 agacgccaga cccgagaccg gtgtctccga taccaattgt tagcaatagc agcggacaag 240
 cagcgaacaa tccgagagac atagtgttggg ggaggagcag atagcttgga gaggaagaag 300
 aacaatagtg acagcgtaga ttctctctcg gtctcctctg ttaccctctc tcaatctaata 360
 actcctatta caaggtcggc ccatcaggcg acccagtcgc ggttccacga acttgggatt 420
 ggggtttgtgc ggacgccgac tggttcttgg ctctgctgga gtcttgtctg tggagctggt 480
 gctcgcgctg ctaacaatct cttgttgttt gcgacgactt cgcgtggcca cgcgttaact 540
 gcgctctgct caaagaaatt gcctatacag tgccctggcgt cagctgcagg cgttgaatcc 600
 gaggtcgcca gtacgaggca aacgctgagc tgcctgctgt accggcttta ttaataactg 660
 agctctactc gctacgttag ctataggcac cagaggcgga tccagagggg gggcaaagta 720
 ggccatggcc cccctcaat tttgtacacc cttttataacc taatgattat ttagtattaa 780
 gtgtagaaaa aatcaaaatt ttagatagta taaaaatctt gttctaaatc tctaaaacta 840
 atagctagtt gctaaaattt gccaaaagggt ttagaatgga tcaactaatt gttagctata 900
 ccctttaaat aagtattaat tgtagatgg cccaacctag ctaaaaccag ttaacagtta 960
 gctctagatg tttagaacat ggcctaaaca accatattat gagcctactc gccggatcct 1020
 ctcggttcag tcttagcatc taccagtctg actctaactc tccgacacc acctaaacca 1080
 gtctgctcgc tgccctgttt ccgccaccga cccattcccg atgcgacgtc accgacttc 1140
 gccctctcgt agcgccctcg tcccttgctc tgtttttctc gtgacgtcga tccgctcgac 1200
 aaattagatc tcgctcgtcg caacgatatg acttatcccc tgcggtcggt ggacttgacg 1260
 aactagaaaa ttatggctct catgtggtct ttttggcccc tcctaaattt tcgtcctgcg 1320
 tccgccactc tatagctgcg ggagtgcggg gtaccgtatc gtgaatctga agtcgaacag 1380
 tgatggcgta ctatctaata tcccgtgcag taatatcact gttgccgacg atgggaatct 1440
 ctagtittga cagaaaccaa ggcaactgct atgctagcta attaattcca gagagat 1497

<210> 10
 <211> 1550
 <212> DNA
 <213> Zea mays

<400> 10
 ctcgagatgt tggatagaag aggaattgcg agcaaccgag gtctccaagg cagcccaacg 60
 cgcacccctgc gcagttaggt ggtcgctgat gtcgcgaagg agcttcgatt gttcgctgat 120
 cgcgagcttc agatttggct ccatgacccc agattgtttg gcgcggcgcg tgtaatgagc 180
 agacgccaga cccgagaccg gtgtctccga taccaattgt tagcaatagc agcggacaag 240
 cagcgaacaa tccgagagac atagtgttggg ggaggagcag atagcttgga gaggaagaag 300
 aacaatagtg acagcgtaga ttctctctcg gtctcctctg ttaccctctc tcaatctaata 360
 actcctatta caaggtcggc ccatcaggcg acccagtcgc ggttccacga acttgggatt 420
 ggggtttgtgc ggacgccgac tggttcttgg ctctgctgga gtcttgtctg tggagctggt 480
 gctcgcgctg ctaacaatct cttgttgttt gcgacgactt cgcgtggcca cgcgttaact 540
 gcgctctgct caaagaaatt gcctatacag tgccctggcgt cagctgcagg cgttgaatcc 600
 gaggtcgcca gtacgaggca aacgctgagc tgcctgctgt accggcttta ttaataactg 660
 agctctactc gctacgttag ctataggcac cagaggcgga tccagagggg gggcaaagta 720
 ggccatggcc cccctcaat tttgtacacc cttttataacc taatgattat ttagtattaa 780
 gtgtagaaaa aatcaaaatt ttagatagta taaaaatctt gttctaaatc tctaaaacta 840

-6-

```

atagctagtt gctaaaatta gccaaaaggt ttagaatgga tcaactaatt gttagctata 900
cccttttaaat aagtattaat tgtagatgg cccaacctag ctaaaaccag ttaacagtta 960
gctctagatg tttagaacat ggccataaca accatattat gagcctactc gccggatcct 1020
ctcggttcag tcctagcacc taccagtctg actctaactc tcccgacacc acctaaacca 1080
gtctgctcgc tgccctgttt ccgccaccga cccattcccg atgcgacgtc acccgacttc 1140
gccccttcgt agcgccctcg tcccttgtec tgtttttctc gtgacgtcga tccgctcgac 1200
aaattagatc tcgctcgteg caacgatatg acttatcccc tgcggtcggg ggacttgacg 1260
aactagaaaa ttatggctct catgtggtct ttttggcccc tcctaaattt tcgtcctgcg 1320
tccgccactc tatagctgcg ggagtgcggg gtaccgtatc gtgaatctga agtcgaacag 1380
tgatggcgta ctatctaata tcccgtgcag taatatcact gttgccgacg atgggaatct 1440
ctagttttga cagaaaccaa ggcaactgct atgctagcta attaatcca gagagatcga 1500
tttctacagt gctagctgca acaatcgatg caattggcat cagacgatat 1550

```

<210> 11

<211> 1710

<212> DNA

<213> Zea mays

<400> 11

```

ctcgagatgt tggatagaag aggaattgcg agcaaccgag gtctccaagg caccgcaacg 60
cgcatcctgc gcagtgaagg ggtcgctgat gtcgcgaagg agcttcgatt gttcgctgat 120
cgcgagcttc agatttggtt ccatgacccc agattgtttg gcgcggcgcg tgtaatgagc 180
agacgccaga cccgagaccg gtgtctccga taccaattgt tagcaatagc agcggacaag 240
cagcgaacaa tccgagagac atagtttggg ggaggagcag atagcttgga gaggaagaag 300
aacaatagtg acagcgtaga ttctctctcg gtctcctctg ttacctctc tcaatctaata 360
actcctatta caaggtcggc ccatcaggcg acccagtcgc ggttccacga acttgggatt 420
gggtttgtgc ggacgccgac tggttcttgg ctctgctgga gtcttgtctg tggagctggt 480
gctcgcgctg ctaacaatct cttgttgttt gcgacgactt cgcgtggcca cgcgttaact 540
gcgctctgct caaagaaatt gcctatacag tgcctggcgt cagctgcagg cgttgaatcc 600
gaggtcgcca gtacgaggca aacgctgagc tgcagtctgt accggcttta ttaataactg 660
agctctactc gctacgttag ctataggcac cagaggcgga tccagagggg gggcaaagta 720
ggccatggcc cccctcaat tttgtacacc cttttatacc taatgattat ttagtattaa 780
gtgtagaaaa aatcaaaatt ttagatagta taaaaatctt gttctaaatc tctaaaacta 840
atagctagtt gctaaaatta gccaaaaggt ttagaatgga tcaactaatt gttagctata 900
cccttttaaat aagtattaat tgtagatgg cccaacctag ctaaaaccag ttaacagtta 960
gctctagatg tttagaacat ggccataaca accatattat gagcctactc gccggatcct 1020
ctcggttcag tcctagcacc taccagtctg actctaactc tcccgacacc acctaaacca 1080
gtctgctcgc tgccctgttt ccgccaccga cccattcccg atgcgacgtc acccgacttc 1140
gccccttcgt agcgccctcg tcccttgtec tgtttttctc gtgacgtcga tccgctcgac 1200
aaattagatc tcgctcgteg caacgatatg acttatcccc tgcggtcggg ggacttgacg 1260
aactagaaaa ttatggctct catgtggtct ttttggcccc tcctaaattt tcgtcctgcg 1320
tccgccactc tatagctgcg ggagtgcggg gtaccgtatc gtgaatctga agtcgaacag 1380
tgatggcgta ctatctaata tcccgtgcag taatatcact gttgccgacg atgggaatct 1440
ctagttttga cagaaaccaa ggcaactgct atgctagcta attaatcca gagagatcga 1500
tttctacagt gctagctgca acaatcgatg caattggcat cagacgatat atgctaattg 1560
ttttctttat cgatacgtgg tcaacagtgc gatccagatt acagagttct ctcgccctga 1620
tcggatctca tcgcacatgg acacccatct gccaaaccaa cgcggggcgg ggaacccgaa 1680
acatcgcgtc catgcacgac cccacgcgag 1710

```

<210> 12

<211> 856

-7-

<212> DNA

<213> Zea mays

<400> 12

```

gtttccctgc ggcatgcagc tggagcgctc ggcgttagtg tcagtccatt ttggagtcgg 60
ttcgtgtacc tgagttttcc ttgaggagat gctgggtttc gctttctttg ttgcaagaat 120
tattagtcag gaataatggg cctcgcgtga ttgtagttcg agtaggtagg tagtccagca 180
tgcaactgac atgtaatggc tactacgagt atatgcttgc atcgccatct tttatttgct 240
gtgccccttg ttgttacagt gttcctcatc gatctttaga ggtcgttgct accgggtttt 300
atcttccaaa acacaaaata tactggaacg actcttgcag tctcttgcta ctgttgaatg 360
tgactattga ctagctaatt agctatagta gcatttatac agttgttgtc aattattata 420
tatagggttg gaaaaaaaaa ctcgagctcg acgacttaka ttgggtctcg cagcagctcc 480
agctcggctt gactcggact ggctcgacgc tcggacgagc ccgagccgag cctatttttg 540
tggctcgtga aaagagcgag ccaactcggc tcgctccaac tcgcgagcta gctcgtggct 600
cgaggtaaca acaattttta catataattc taattagcat ataattagc taccgagtat 660
acaattaatt tatgttattt gagattacta taaaaattaa tctagtatta gtgatataac 720
tattttacta atttaaaaata tgttatttaa aatattttta agattttata ttataattta 780
gagagcagat ctacgtttat agctagtacc gagctgcttt ttccagctca ccagatgggt 840
gcgcgaacc gagctc

```

<210> 13

<211> 440

<212> DNA

<213> Zea mays

<400> 13

```

gtttccctgc ggcatgcagc tggagcgctc ggcgttagtg tcagtccatt ttggagtcgg 60
ttcgtgtacc tgagttttcc ttgaggagat gctgggtttc gctttctttg ttgcaagaat 120
tattagtcag gaataatggg cctcgcgtga ttgtagttcg agtaggtagg tagtccagca 180
tgcaactgac atgtaatggc tactacgagt atatgcttgc atcgccatct tttatttgct 240
gtgccccttg ttgttacagt gttcctcatc gatctttaga ggtcgttgct accgggtttt 300
atcttccaaa acacaaaata tactggaacg actcttgcag tctcttgcta ctgttgaatg 360
tgactattga ctagctaatt agctatagta gcatttatac agttgttgtc aattattata 420
tatagggttg gaaaaaaaaa

```

<210> 14

<211> 3416

<212> DNA

<213> Zea mays

<400> 14

```

ctcgagatgt tggatagaag aggaattgct agcaaccgag gtctccaagg cacgccaacg 60
cgcacctctg gcagtgaggt ggtcgtgat gtcgcgaagg agcttcgatt gtctcgtgat 120
cgcgagcttc agatttggtt ccatgacccc agattgtttg gcgcggcgcg tgtaatgagc 180
agacgccaga cccgagaccg gtgtctccga taccaattgt tagcaatagc agcggacaag 240
cagcgaacaa tccgagagac atagtttggg ggaggagcag atagcttgga gaggaagaag 300
aacaatagt acagcgtaga ttctctctct gtctcctctg ttaccctctc tcaatctaata 360
actcctatta caaggtcggc ccatcaggcg acccagtcgc ggttcacga acttgggatt 420
gggtttgtgc ggacgccgac tggttcttgg ctctgctgga gtcttgctg ttgagctggt 480
gctcgcgctg ctaacaatct cttgttggtt gcgacgactt cgcgtggcca cgcgttaact 540
gcgctctgct caaagaaatt gcctatacag tgccctggcgt cagctgcagg cgttgaatcc 600

```

```

gaggtcgcca gtacgaggca aacgctgagc tgcattgctgt accggcttta ttaataactg 660
agctctactc gctacgttag ctataggcac cagaggcgga tccagagggg gggcaaagta 720
ggccatggcc cccctcaat tttgtacacc cttttatacc taatgattat ttagtattaa 780
gtgtagaaaa aatcaaaatt ttagatagta taaaaatctt gttctaaatc tctaaaacta 840
atagctagtt gctaaaatta gccaaaaggt ttagaatgga tcaactaatt gttagctata 900
ccctttaaat aagtattaat tgttagatgg cccaacctag ctaaaaccag ttaacagtta 960
gctctagatg tttagaacat ggccataaca accatattat gagcctactc gccggatcct 1020
ctcggttcag tcttagcatc taccagtctg actctaactc tcccgacacc acctaaacca 1080
gtctgctcgc tgcctgttt ccgccaccga cccattcccg atgcgacgac acccgacttc 1140
gccccttcgt agcgccctcg tccctgtgcc tgtttttctc gtgacgtcga tccgctcgac 1200
aaattagatc tcgctcgctg caacgatatg acttatcccc tgcggtcggt ggacttgacg 1260
aactagaaaa ttatggctct catgtggtct ttttggcccc tctaaattt tcgtcctgcg 1320
tccgccactc tatagctgcg ggagtgcggg gtaccgtatc gtgaatctga agtcgaacag 1380
tgatggcgta ctatctaatt tcccgtgcag taatatcact gttgccgacg atgggaatct 1440
ctagttttga cagaaacca ggcaactgct atgctagcta attaattcca gagagatcga 1500
tttctacagt gctagctgca acaatcgatg caattggcat cagacgatat atgctaattg 1560
ttttctttat cgatacgtgg tcaacagtgc gatccagatt acagagttct ctcgccctga 1620
tcggatctca tcgcacatgg acaccatct gccaaaccaa cgcggggcgg ggaaccgcaa 1680
acatcgctc catgcacgac cccacgcgac ctataaatat ccatgcaatg caatgcagcg 1740
ggatcatc atcgactcca cctggactcg ctcactggca atggctacca gcaccaagct 1800
cgtggccctt ggcttggccg tccctgtgag cgttgggttc tccgatgcag cgagggtagc 1860
taggcttggg agctatgctg ctgccggagg tggcgcgggc ggtggaggcg gcggctccgg 1920
atcgaccggg gctgggtacg gcggtgggtc tggcggtggc ggtggctacg gcataggcaa 1980
gggtggcggg gactggtgga acaatttcgt ctccagcgta gcggcggtg gtggtggggg 2040
gcaaggcgga ggaggtggca ccaacggtgg atccgggtcc ggcggtgggt cgggctatgg 2100
ttctggcacc agttccaccg cagcctctgg cccagcagat ggcaactacg ccaacgctga 2160
gggcaagggc gccggtgggg gcatgggcgg tgggtccgac gcccgacggc cctacggttc 2220
tgggtccggt ggagggcgtg gcaagggccca gggcgagagt ggcgtcgcat tggcacgctc 2280
gtccgatggc tactacaatg gcgcgccgc tgatgctacc ggtggtggtt ccggcgctgg 2340
cgggtggacat ggcggtggcg cagccggagc tccaagctac gggactggag gtggccttgg 2400
cggaggcaag ggcgaggccg gcagcgacgg gtcctggggg tcaggttacg cggcggaat 2460
cgggtgccggc actggcgcg gcggtggcg cggatcgcaa ggcggtctg gtggtggcg 2520
cggctctggg tccggatccg gcagcggtgg aatccactga gtttccctgc ggcagtcagc 2580
tggagcgctc ggcgttagtg tcagtcatt ttggagtcgg ttcgtgtacc tgagttttcc 2640
ttgaggagat gctggttttc gctttctttg ttgcaagaat tattagtcag gaataatggg 2700
cctcgctga ttgtagttcg agtaggtagg tagtccagca tgcaactgac atgtaatggc 2760
tactacgagt atatgcttg atcgccatct tttatttgct gtgccccttg ttgttacagt 2820
gttccctcat gatctttaga ggtcgttgct accggttttt atcttccaaa acacaaaata 2880
tactggaacg actcttgcat tctcttgcta ctgttgatg tgactattga ctagctaatt 2940
agctatagta gcatttatac agttgttgct aattattata tatagggttg gaaaaaaaaa 3000
ctcgagctcg acgacttaga ttgggtctcg cagcagctcc agctcggtt gactcggact 3060
ggctcgacgc tcggacgagc ccgagccgag cctatttttg tggctcgtga aaagagcgag 3120
ccaactcggc tcgctccaac tcgagagcta gctcgtggct cgaggtaaca acaattttta 3180
catataattc taattagcat ataattattg taccgagtat acaattaatt tatgttattt 3240
gagattacta taaaaattaa tctagtatta gtgatatact tattttacta atttaaaata 3300
tgttatttaa aatattttta agattttata ttataattta gagagcagat ctacgtttat 3360
agctagtacc gagctgcttt ttccagctca ccagatgggt gcgccgaacc gagctc 3416

```

<210> 15

<211> 1074

<212> DNA

<213> Zea mays

<400> 15

```
ggctcgttgc atgagcgagc cgagtcaagc tcgggttggc tcgtttccac ccctagttat 60
atacgatcaa attggaccgc acgacactga cattaacact attaaacata acactattat 120
taatcgtgtc gtgctatatt agcattagtg actagctatc ggtacagaca tgacactata 180
ttgcctaata atgtcgtgcc tgacactata tagaggggat ctctagtagt ttttctatct 240
tagttcctat ctgtcggtag cctgaaacta gggatatccct tactattgta taaagacgca 300
gtacccacgc ggctatcttt agacgcgtgg taaacgagct gtatgtggga ccaggccatg 360
actcgcccca gcctcgggcg actactctag gccagcaaca gcgcttgacc ccaccacatg 420
ggcgggtccg cggccgccac gtgtccagag aaagtgatat actccaaggc atcaacagtg 480
agtcgggaca tgggagagtg tcggacccat gccggacccc tgtatatacg gtccaggcct 540
ccaagtttgg ccagggacct taggccattg ccgctgtcgc ccggcgggtg aatgagtatc 600
atgtcgtagc tgccgtcgag ggacatgaac tcaagactcc cgaaacggag caccttcccg 660
ggttggagag gttgctggag actgcccata tggagcttga cgggaagctg ttcgtcaaca 720
cgcagcaggc ccctacctgg cgcgccaaact gtccggcgttt cgagaccggg gggtcacctaa 780
gccgacgagt gaatctcgcc gcgtgcecca gccagatgg gtcgacgcga ggccgagcgc 840
gaagggggga agtgagggtg ccggagatag gcgtgagaga ggtgcaaata ccgcggcctc 900
cgtgttcgtc tcgcgcccag gtcgggtgcg cttgcagtag ggggttacia gcgtccacgc 960
gggagagggg gcaagcggcc taacacgagc gcatgtctcg tcctcgtccc cgcgcggcca 1020
accctatcta agagggccct ggtccttctt tttataggcg taaggagagg atcc 1074
```

INTERNATIONAL SEARCH REPORT

ional Application No

CT/EP 99/06692

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/43 C12N15/29 C12N15/10 C12N15/82 A01H1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	GODDEMEIER M L ET AL., : "Root-specific expression of a Zea mays gene encoding a novel glycine-rich protein, zmGRP3." PLANT MOLECULAR BIOLOGY, vol. 36, no. 5, March 1998 (1998-03), page 799-802 XP002128334 the whole document	4-6
X	SANMIGUEL P.J. ET AL., : "Nested retrotransposons in the intergenic regions of the maize genome" SCIENCE, vol. 274, 1996, page 765-768 XP000867133 the whole document	4,5

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

21 January 2000

Date of mailing of the international search report

10/02/2000

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

onal Application No

PCT/EP 99/06692

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	EDWARDS K.J. ET AL., : "Characterization of four dispersed repetitive DNA sequences from Zea mays and the use in constructing contiguous fragments using YAC clones" GENOME , vol. 39, 1996, page 811-817 XP000869516 the whole document	4,5
Y	WO 94 02619 A (PIONEER HI BRED INT) 3 February 1994 (1994-02-03) cited in the application abstract page 5, line 1 -page 6, line 18 page 15, line 34 -page 27, line 9	1-25
Y	EP 0 337 532 A (MOGEN INT ;UNIV LEIDEN (NL)) 18 October 1989 (1989-10-18) abstract column 1, line 1-10 column 2, line 45 -column 9, line 23	1-25
A	US 5 633 363 A (COLBERT JAMES T ET AL) 27 May 1997 (1997-05-27) abstract column 1, line 28 -column 2, line 25; examples 6-8	1-10, 15-25
A	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 23 April 1991 (1991-04-23), XP002128337 HINXTON, GB AC= X57663. Sorghum vulgare mRNA for glycine-rich RNA-binding protein (clone S1) abstract	4
A	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 26 August 1991 (1991-08-26), XP002128338 HINXTON, GB AC= AF010580. Oryza sativa glycine-rich protein (OSGRP2) mRNA, complete cds. abstract	4
P, X	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 22 August 1999 (1999-08-22), XP002128339 HINXTON, GB AC = AI948280. Zea mays cDNA, mRNA sequence. EST sequence. abstract	1,2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/06692

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9402619	A	03-02-1994	US 5401836 A	28-03-1995
			AT 166108 T	15-05-1998
			AU 672618 B	10-10-1996
			AU 4673893 A	14-02-1994
			BR 9306737 A	08-12-1998
			CA 2140014 A	03-02-1994
			DE 69318558 D	18-06-1998
			DE 69318558 T	10-09-1998
			EP 0651813 A	10-05-1995
			JP 8501923 T	05-03-1996
			MX 9304285 A	29-07-1994
			NZ 254577 A	25-06-1996
EP 0337532	A	18-10-1989	NL 8800725 A	16-10-1989
			DE 68928892 D	18-02-1999
			DE 68928892 T	05-08-1999
			JP 2042991 A	13-02-1990
			US 5057422 A	15-10-1991
US 5633363	A	27-05-1997	NONE	

PCT

ANTRAG

Der Unterzeichnete beantragt, daß die vorliegende internationale Anmeldung nach dem Vertrag über die internationale Zusammenarbeit auf dem Gebiet des Patentwesens behandelt wird.

V meldeamt auszufüllen	
Internationales Aktenzeichen	
Internationales Anmeldedatum	
Name des Anmeldeamts und "PCT International Application"	
Aktenzeichen des Anmelders oder Anwalts (falls gewünscht) (max. 12 Zeichen) 23143 WO	

Feld Nr. I BEZEICHNUNG DER ERFINDUNG

Regulatory Sequences for Root Specific or Root Abundant Gene Expression in Plants

Feld Nr. II ANMELDER

Name und Anschrift: (Familienname, Vorname; bei juristischen Personen vollständige amtliche Bezeichnung. Bei der Anschrift sind die Postleitzahl und der Name des Staats anzugeben. Der in diesem Feld in der Anschrift angegebene Staat ist der Staat des Sitzes oder Wohnsitzes des Anmelders, sofern nachstehend kein Staat des Sitzes oder Wohnsitzes angegeben ist.)

Agricultural Technology &
Genetics GmbH
Im Rheinfeld 1-13
D-76437 RASTATT
DE

☐ Diese Person ist gleichzeitig Erfinder

Telefonnr.:

Telefaxnr.:

Fernschreibnr.:

Staatsangehörigkeit (Staat):

DE

Sitz oder Wohnsitz (Staat):

DE

Diese Person ist Anmelder für folgende Staaten:

☐ alle Bestimmungsstaaten

☒ alle Bestimmungsstaaten mit Ausnahme der Vereinigten Staaten von Amerika

☐ nur die Vereinigten Staaten von Amerika

☐ die im Zusatzfeld angegebenen Staaten

Feld Nr. III WEITERE ANMELDER UND/ODER (WEITERE) ERFINDER

Name und Anschrift: (Familienname, Vorname; bei juristischen Personen vollständige amtliche Bezeichnung. Bei der Anschrift sind die Postleitzahl und der Name des Staats anzugeben. Der in diesem Feld in der Anschrift angegebene Staat ist der Staat des Sitzes oder Wohnsitzes des Anmelders, sofern nachstehend kein Staat des Sitzes oder Wohnsitzes angegeben ist.)

Feix, Günter
Rehagweg 13
D-79100 FREIBURG
DE

Diese Person ist:

☐ nur Anmelder

☒ Anmelder und Erfinder

☐ nur Erfinder (Wird dieses Kästchen angekreuzt, so sind die nachstehenden Angaben nicht nötig.)

Staatsangehörigkeit (Staat):

DE

Sitz oder Wohnsitz (Staat):

DE

Diese Person ist Anmelder für folgende Staaten:

☐ alle Bestimmungsstaaten

☐ alle Bestimmungsstaaten mit Ausnahme der Vereinigten Staaten von Amerika

☒ nur die Vereinigten Staaten von Amerika

☐ die im Zusatzfeld angegebenen Staaten

☒ Weitere Anmelder und/oder (weitere) Erfinder sind auf einem Fortsetzungsblatt angegeben.

Feld Nr. IV ANWALT ODER GEMEINSAMER VERTRETER; ODER ZUSTELLANSCHRIFT

Die folgende Person wird hiermit bestellt/ist bestellt worden, um für den (die) Anmelder vor den zuständigen internationalen Behörden in folgender Eigenschaft zu handeln als:

☒ Anwalt

☐ gemeinsamer Vertreter

Name und Anschrift: (Familienname, Vorname; bei juristischen Personen vollständige amtliche Bezeichnung. Bei der Anschrift sind die Postleitzahl und der Name des Staats anzugeben.)

Schrell, Andreas; Gleiss, Alf-Olav;
Große, Rainer
Maybachstraße 6A
D-70469 STUTTGART
DE

Telefonnr.:

0711/81 45 55

Telefaxnr.:

0711/81 30 32

Fernschreibnr.:

☐ **Zustellanschrift:** Dieses Kästchen ist anzukreuzen, wenn kein Anwalt oder gemeinsamer Vertreter bestellt ist und stattdessen im obigen Feld eine spezielle Zustellanschrift angegeben ist.

Fortsetzung von Feld Nr. III WEITERE ANMELDER UND/ODER (WEITERE) ERFINDER

Wird keines der folgenden Felder benutzt, so sollte dieses Blatt dem Antrag nicht beigelegt werden.

Name und Anschrift: (Familienname, Vorname; bei juristischen Personen vollständige amtliche Bezeichnung. Bei der Anschrift sind die Postleitzahl und der Name des Staats anzugeben. Der in diesem Feld in der Anschrift angegebene Staat ist der Staat des Sitzes oder Wohnsitzes des Anmelders, sofern nachstehend kein Staat des Sitzes oder Wohnsitzes angegeben ist.)

Wulff, Doerte
Buchenstraße 10
D-79108 FREIBURG
DE

Diese Person ist:

- ☐ nur Anmelder
- ☐ Anmelder und Erfinder
- ☐ nur Erfinder (Wird dieses Kästchen angekreuzt, so sind die nachstehenden Angaben nicht nötig.)

Staatsangehörigkeit (Staat):

DE

Sitz oder Wohnsitz (Staat):

DE

Diese Person ist Anmelder für folgende Staaten:

- ☐ alle Bestimmungsstaaten ☐ alle Bestimmungsstaaten mit Ausnahme der Vereinigten Staaten von Amerika ☒ nur die Vereinigten Staaten von Amerika ☐ die im Zusatzfeld angegebenen Staaten

Name und Anschrift: (Familienname, Vorname; bei juristischen Personen vollständige amtliche Bezeichnung. Bei der Anschrift sind die Postleitzahl und der Name des Staats anzugeben. Der in diesem Feld in der Anschrift angegebene Staat ist der Staat des Sitzes oder Wohnsitzes des Anmelders, sofern nachstehend kein Staat des Sitzes oder Wohnsitzes angegeben ist.)

Diese Person ist:

- ☐ nur Anmelder
- ☐ Anmelder und Erfinder
- ☐ nur Erfinder (Wird dieses Kästchen angekreuzt, so sind die nachstehenden Angaben nicht nötig.)

Staatsangehörigkeit (Staat):

Sitz oder Wohnsitz (Staat):

Diese Person ist Anmelder für folgende Staaten:

- ☐ alle Bestimmungsstaaten ☐ alle Bestimmungsstaaten mit Ausnahme der Vereinigten Staaten von Amerika ☐ nur die Vereinigten Staaten von Amerika ☐ die im Zusatzfeld angegebenen Staaten

Name und Anschrift: (Familienname, Vorname; bei juristischen Personen vollständige amtliche Bezeichnung. Bei der Anschrift sind die Postleitzahl und der Name des Staats anzugeben. Der in diesem Feld in der Anschrift angegebene Staat ist der Staat des Sitzes oder Wohnsitzes des Anmelders, sofern nachstehend kein Staat des Sitzes oder Wohnsitzes angegeben ist.)

Diese Person ist:

- ☐ nur Anmelder
- ☐ Anmelder und Erfinder
- ☐ nur Erfinder (Wird dieses Kästchen angekreuzt, so sind die nachstehenden Angaben nicht nötig.)

Staatsangehörigkeit (Staat):

Sitz oder Wohnsitz (Staat):

Diese Person ist Anmelder für folgende Staaten:

- ☐ alle Bestimmungsstaaten ☐ alle Bestimmungsstaaten mit Ausnahme der Vereinigten Staaten von Amerika ☐ nur die Vereinigten Staaten von Amerika ☐ die im Zusatzfeld angegebenen Staaten

Name und Anschrift: (Familienname, Vorname; bei juristischen Personen vollständige amtliche Bezeichnung. Bei der Anschrift sind die Postleitzahl und der Name des Staats anzugeben. Der in diesem Feld in der Anschrift angegebene Staat ist der Staat des Sitzes oder Wohnsitzes des Anmelders, sofern nachstehend kein Staat des Sitzes oder Wohnsitzes angegeben ist.)

Diese Person ist:

- ☐ nur Anmelder
- ☐ Anmelder und Erfinder
- ☐ nur Erfinder (Wird dieses Kästchen angekreuzt, so sind die nachstehenden Angaben nicht nötig.)

Staatsangehörigkeit (Staat):

Sitz oder Wohnsitz (Staat):

Diese Person ist Anmelder für folgende Staaten:

- ☐ alle Bestimmungsstaaten ☐ alle Bestimmungsstaaten mit Ausnahme der Vereinigten Staaten von Amerika ☐ nur die Vereinigten Staaten von Amerika ☐ die im Zusatzfeld angegebenen Staaten

☐ Weitere Anmelder und/oder (weitere) Erfinder sind auf einem zusätzlichen Fortsetzungsblatt angegeben.

Feld Nr. V BESTIMMUNG STAATEN

Die folgenden Bestimmungen nach Regel 4.9 Absatz a werden hiermit vorgenommen (bitte die entsprechenden Kästchen ankreuzen; wenigstens ein Kästchen muß angekreuzt werden):

Regionales Patent

- ☒ AP **ARIPO-Patent:** GH Ghana, GM Gambia, KE Kenia, LS Lesotho, MW Malawi, SD Sudan, SZ Swasiland, UG Uganda, ZW Simbabwe und jeder weitere Staat, der Vertragsstaat des Harare-Protokolls und des PCT ist
- ☒ EA **Eurasisches Patent:** AM Armenien, AZ Aserbaidshan, BY Belarus, KG Kirgisistan, KZ Kasachstan, MD Republik Moldau, RU Russische Föderation, TJ Tadschikistan, TM Turkmenistan und jeder weitere Staat, der Vertragsstaat des Eurasischen Patentübereinkommens und des PCT ist
- ☒ EP **Europäisches Patent:** AT Österreich, BE Belgien, CH und LI Schweiz und Liechtenstein, CY Zypern, DE Deutschland, DK Dänemark, ES Spanien, FI Finnland, FR Frankreich, GB Vereinigtes Königreich, GR Griechenland, IE Irland, IT Italien, LU Luxemburg, MC Monaco, NL Niederlande, PT Portugal, SE Schweden und jeder weitere Staat, der Vertragsstaat des Europäischen Patentübereinkommens und des PCT ist
- ☒ OA **OAPI-Patent:** BF Burkina Faso, BJ Benin, CF Zentralafrikanische Republik, CG Kongo, CI Côte d'Ivoire, CM Kamerun, GA Gabun, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauretanien, NE Niger, SN Senegal, TD Tschad, TG Togo und jeder weitere Staat, der Vertragsstaat der OAPI und des PCT ist (falls eine andere Schutzrechtsart oder ein sonstiges Verfahren gewünscht wird, bitte auf der gepunkteten Linie angeben)

Nationales Patent (falls eine andere Schutzrechtsart oder ein sonstiges Verfahren gewünscht wird, bitte auf der gepunkteten Linie angeben):

- | | |
|--|--|
| <input checked="" type="checkbox"/> AL Albanien | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AM Armenien | <input checked="" type="checkbox"/> LT Litauen |
| <input checked="" type="checkbox"/> AT Österreich | <input checked="" type="checkbox"/> LU Luxemburg |
| <input checked="" type="checkbox"/> AU Australien | <input checked="" type="checkbox"/> LV Lettland |
| <input checked="" type="checkbox"/> AZ Aserbaidshan | <input checked="" type="checkbox"/> MD Republik Moldau |
| <input checked="" type="checkbox"/> BA Bosnien-Herzegowina | <input checked="" type="checkbox"/> MG Madagaskar |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MK Die ehemalige jugoslawische Republik Mazedonien |
| <input checked="" type="checkbox"/> BG Bulgarien | <input checked="" type="checkbox"/> MN Mongolei |
| <input checked="" type="checkbox"/> BR Brasilien | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MX Mexiko |
| <input checked="" type="checkbox"/> CA Kanada | <input checked="" type="checkbox"/> NO Norwegen |
| <input checked="" type="checkbox"/> CH und LI Schweiz und Liechtenstein | <input checked="" type="checkbox"/> NZ Neuseeland |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> PL Polen |
| <input checked="" type="checkbox"/> CU Kuba | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> CZ Tschechische Republik | <input checked="" type="checkbox"/> RO Rumänien |
| <input checked="" type="checkbox"/> DE Deutschland | <input checked="" type="checkbox"/> RU Russische Föderation |
| <input checked="" type="checkbox"/> DK Dänemark | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> EE Estland | <input checked="" type="checkbox"/> SE Schweden |
| <input checked="" type="checkbox"/> ES Spanien | <input checked="" type="checkbox"/> SG Singapur |
| <input checked="" type="checkbox"/> FI Finnland | <input checked="" type="checkbox"/> SI Slowenien |
| <input checked="" type="checkbox"/> GB Vereinigtes Königreich | <input checked="" type="checkbox"/> SK Slowakei |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GE Georgien | <input checked="" type="checkbox"/> TJ Tadschikistan |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TR Türkei |
| <input checked="" type="checkbox"/> HR Kroatien | <input checked="" type="checkbox"/> TT Trinidad und Tobago |
| <input checked="" type="checkbox"/> HU Ungarn | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> ID Indonesien | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> US Vereinigte Staaten von Amerika |
| <input checked="" type="checkbox"/> IN Indien | |
| <input checked="" type="checkbox"/> IS Island | |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> UZ Usbekistan |
| <input checked="" type="checkbox"/> KE Kenia | <input checked="" type="checkbox"/> VN Vietnam |
| <input checked="" type="checkbox"/> KG Kirgisistan | <input checked="" type="checkbox"/> YU Jugoslawien |
| <input checked="" type="checkbox"/> KP Demokratische Volksrepublik Korea | <input checked="" type="checkbox"/> ZW Simbabwe |
| | |
| <input checked="" type="checkbox"/> KR Republik Korea | |
| <input checked="" type="checkbox"/> KZ Kasachstan | |
| <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> ZA Südafrika |
| <input checked="" type="checkbox"/> LK Sri Lanka | <input type="checkbox"/> |
| <input checked="" type="checkbox"/> LR Liberia | <input type="checkbox"/> |

Kästchen für die Bestimmung von Staaten (für die Zwecke eines nationalen Patents), die dem PCT nach der Veröffentlichung dieses Formblatts beigetreten sind:

Erklärung bzgl. vorsorglicher Bestimmungen: Zusätzlich zu den oben genannten Bestimmungen nimmt der Anmelder nach Regel 4.9 Absatz b auch alle anderen nach dem PCT zulässigen Bestimmungen vor mit Ausnahme der im Zusatzfeld genannten Bestimmungen, die von dieser Erklärung ausgenommen sind. Der Anmelder erklärt, daß diese zusätzlichen Bestimmungen unter dem Vorbehalt einer Bestätigung stehen und jede zusätzliche Bestimmung, die vor Ablauf von 15 Monaten ab dem Prioritätsdatum nicht bestätigt wurde, nach Ablauf dieser Frist als vom Anmelder zurückgenommen gilt. (Die Bestätigung einer Bestimmung erfolgt durch die Einreichung einer Mitteilung, in der diese Bestimmung angegeben wird, und die Zahlung der Bestimmungs- und der Bestätigungsgebühr. Die Bestätigung muß beim Anmeldeamt innerhalb der Frist von 15 Monaten eingehen.)

Feld Nr. VI PRIORITÄTSANMELDUNG		<input type="checkbox"/> Weitere Prioritätsansprüche sind im Zusatzfeld angegeben.		
Anmeldedatum der früheren Anmeldung (Tag/Monat/Jahr)	Aktenzeichen der früheren Anmeldung	Ist die frühere Anmeldung eine:		
		nationale Anmeldung: Staat	regionale Anmeldung: * regionales Amt	internationale Anmeldung: Anmeldeamt
Zeile(1) 11. September 1998 (11.09.1998)	98117251.3		EP	
Zeile(2)				
Zeile(3)				

☒ Das Anmeldeamt wird ersucht, eine beglaubigte Abschrift der oben in der (den) Zeile(n) _____ bezeichneten früheren Anmeldung(en) zu erstellen und dem internationalen Büro zu übermitteln (nur falls die frühere Anmeldung(en) bei dem Amt eingereicht worden ist(sind), das für die Zwecke dieser internationalen Anmeldung Anmeldeamt ist)

* Falls es sich bei der früheren Anmeldung um eine ARIPO-Anmeldung handelt, so muß in dem Zusatzfeld mindestens ein Staat angegeben werden, der Mitgliedstaat der Pariser Verbandsübereinkunft zum Schutz des gewerblichen Eigentums ist und für den die frühere Anmeldung eingereicht wurde.

Feld Nr. VII INTERNATIONALE RECHERCHENBEHÖRDE

Wahl der internationalen Recherchenbehörde (ISA) (falls zwei oder mehr als zwei internationale Recherchen- behörden für die Ausführung der internationalen Recherche zuständig sind, geben Sie die von Ihnen gewählte Behörde an; der Zweibuchstaben-Code kann benutzt werden)	Antrag auf Nutzung der Ergebnisse einer früheren Recherche; Bezugnahme auf diese frühere Recherche (falls eine frühere Recherche bei der internationalen Recherchenbehörde beantragt oder von ihr durchgeführt worden ist): Datum (Tag/Monat/Jahr) Aktenzeichen Staat (oder regionales Amt)
ISA / EPA	

Feld Nr. VIII KONTROLLISTE; EINREICHUNGSSPRACHE

Diese internationale Anmeldung enthält die folgende Anzahl von Blättern: Antrag : 4 Beschreibung (ohne Sequenzprotokollteil) : 36 Ansprüche : 5 Zusammenfassung : 1 Zeichnungen : 5 Sequenzprotokollteil der Beschreibung : 8 Blattzahl insgesamt : 59	Dieser internationalen Anmeldung liegen die nachstehend angekreuzten Unterlagen bei: 1. <input checked="" type="checkbox"/> Blatt für die Gebührenberechnung 2. <input type="checkbox"/> Gesonderte unterzeichnete Vollmacht 3. <input type="checkbox"/> Kopie der allgemeinen Vollmacht; Aktenzeichen (falls vorhanden): 4. <input type="checkbox"/> Begründung für das Fehlen einer Unterschrift 5. <input type="checkbox"/> Prioritätsbeleg(e), in Feld Nr. VI durch folgende Zeilennummer gekennzeichnet: 6. <input type="checkbox"/> Übersetzung der internationalen Anmeldung in die folgende Sprache: 7. <input type="checkbox"/> Gesonderte Angaben zu hinterlegten Mikroorganismen oder anderem biologischen Material 8. <input checked="" type="checkbox"/> Protokoll der Nucleotid- und/oder Aminosäuresequenzen in computerlesbarer Form 9. <input type="checkbox"/> Sonstige (einzeln auflisten):
--	--

Abbildung der Zeichnungen, die
mit der Zusammenfassung
veröffentlicht werden soll (Nr.):

Sprache, in der die
internationale Anmeldung
eingereicht wird: Englisch

Feld Nr. IX UNTERSCHRIFT DES ANMELDERS ODER DES ANWALTS

Der Name jeder unterzeichnenden Person ist neben der Unterschrift zu wiederholen, und es ist anzugeben, sofern sich dies nicht eindeutig aus dem Antrag ergibt, in welcher Eigenschaft die Person unterzeichnet.

Dr. Andreas Schrell, European Patent Attorney

09.09.1999

Vom Anmeldeamt auszufüllen	
1. Datum des tatsächlichen Eingangs dieser internationalen Anmeldung:	2. Zeichnungen <input type="checkbox"/> eingegangen: <input type="checkbox"/> nicht eingegangen:
3. Geändertes Eingangsdatum aufgrund nachträglich, jedoch fristgerecht eingegangener Unterlagen oder Zeichnungen zur Vervollständigung dieser internationalen Anmeldung:	
4. Datum des fristgerechten Eingangs der angeforderten Richtigstellungen nach Artikel 11(2) PCT:	
5. Internationale Recherchenbehörde (falls zwei oder mehr zuständig sind): ISA /	6. <input type="checkbox"/> Übermittlung des Recherchenexemplars bis zur Zahlung der Recherchegebühr aufgeschoben

Vom Internationalen Büro auszufüllen
Datum des Eingangs des Aktenexemplars beim Internationalen Büro:

PCT

BLATT FÜR DIE GEBÜHRENBERECHNUNG

Anhang zum Antrag

Von Anmeldeamt auszufüllen

Internationales Aktenzeichen

Eingangsstempel des Anmeldeamts

Aktenzeichen des Anmelders
oder Anwalts

23143 WO

Anmelder

Agricultural Technology & Genetics GmbH

BERECHNUNG DER VORGESCHRIEBENEN GEBÜHREN

1. ÜBERMITTLUNGSGEBÜHR DM 199,49 T

2. RECHERCHENGEBÜHR DM 1.848,26 S

Die internationale Recherche ist durchzuführen von EPA
(Sind zwei oder mehr Internationale Recherchenbehörden für die internationale Recherche zuständig,
ist der Name der Behörde anzugeben, die die internationale Recherche durchführen soll.)

3. INTERNATIONALE GEBÜHR

Grundgebühr

Die internationale Anmeldung enthält 59 Blätter.

umfaßt die ersten 30 Blätter DM 807,76 b1

29 x 19,56 = DM 567,24 b2

Anzahl der Blätter über 30 Zusatzblattgebühr

Addieren Sie die in Feld b1 und b2 eingetragenen Beträge, und tragen Sie die Summe in Feld B ein DM 1.375,00 B

Bestimmungsgebühren

Die internationale Anmeldung enthält alle Bestimmungen.

10 x DM 185,80 = DM 1.858,00 D

Anzahl der zu zahlenden Bestimmungengebühr

Bestimmungsgebühren (maximal 10)

Addieren Sie die in Feld B und D eingetragenen Beträge, und tragen Sie die Summe in Feld I ein DM 3.233,00 I

(Anmelder aus einigen Staaten haben Anspruch auf eine Ermäßigung der internationalen Gebühr um 75%.
Hat der Anmelder (oder haben alle Anmelder) einen solchen Anspruch, so beträgt der in Feld I einzutragende Gesamtbetrag 25% der Summe der in Feld B und D eingetragenen Beträge.)

4. GEBÜHR FÜR PRIORITÄTSBELEG (ggf.) DM 58,67 P

5. GESAMTBETRAG DER ZU ZAHLENDEN GEBÜHREN

Addieren Sie die in Feldern T, S, I und P eingetragenen Beträge, und tragen Sie die Summe in das nebenstehende Feld ein DM 5.339,42

INSGESAMT

☐ Die Bestimmungsgebühren werden jetzt noch nicht gezahlt.

ZAHLUNGSWEISE

☒ Abbuchungsauftrag (siehe unten)

☐ Bankwechsel

☐ Kupons

☐ Scheck

☐ Barzahlung

☐ Sonstige (einzeln angeben):

☐ Postanweisung

☐ Gebührenmarken

ABBUCHUNGSauftrag (diese Zahlungsweise gibt es nicht bei allen Anmeldeämtern)

Das Anmeldeamt/ EPA

☒ wird beauftragt, den vorstehend angegebenen Gesamtbetrag der Gebühren von meinem laufenden Konto abzubuchen.

☒ (dieses Kästchen darf nur angekreuzt werden, wenn die Vorschriften des Anmeldeamts über laufende Konten dieses Verfahren erlauben) wird beauftragt, Fehlbeträge oder Überzahlungen des vorstehend angegebenen Gesamtbetrags der Gebühren meinem laufenden Konto zu belasten bzw. gutzuschreiben.

☐ wird beauftragt, die Gebühr für die Ausstellung des Prioritätsbelegs und seine Übermittlung an das Internationale Büro der WIPO von meinem laufenden Konto abzubuchen.

28000629

09.09.1999

Dr. Andreas Schrell

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 23143 WO	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/EP 99/ 06692	International filing date (day/month/year) 10/09/1999	(Earliest) Priority Date (day/month/year) 11/09/1998
Applicant AGRICULTURAL TECHNOLOGY & GENETICS GMBH et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the title,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

- ☐ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.
- ☐ None of the figures.

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07K14/43 C12N15/29 C12N15/10 C12N15/82 A01H1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>✓ GODDEMEIER M L ET AL., : "Root-specific expression of a Zea mays gene encoding a novel glycine-rich protein, zmGRP3." PLANT MOLECULAR BIOLOGY, vol. 36, no. 5, March 1998 (1998-03), page 799-802 XP002128334 the whole document</p> <p>---</p>	4-6
X	<p>✓ SANMIGUEL P.J. ET AL., : "Nested retrotransposons in the intergenic regions of the maize genome" SCIENCE, vol. 274, 1996, page 765-768 XP000867133 the whole document</p> <p>---</p> <p>-/--</p>	4,5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 January 2000

Date of mailing of the international search report

10/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EDWARDS K.J. ET AL., : "Characterization of four dispersed repetitive DNA sequences from Zea mays and the use in constructing contiguous fragments using YAC clones" GENOME, vol. 39, 1996, page 811-817 XP000869516 the whole document	4,5
Y	WO 94 02619 A (PIONEER HI BRED INT) 3 February 1994 (1994-02-03) cited in the application abstract page 5, line 1 -page 6, line 18 page 15, line 34 -page 27, line 9	1-25
Y	EP 0 337 532 A (MOGEN INT ;UNIV LEIDEN (NL)) 18 October 1989 (1989-10-18) abstract column 1, line 1-10 column 2, line 45 -column 9, line 23	1-25
A	US 5 633 363 A (COLBERT JAMES T ET AL) 27 May 1997 (1997-05-27) abstract column 1, line 28 -column 2, line 25; examples 6-8	1-10, 15-25
A	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 23 April 1991 (1991-04-23), XP002128337 HINXTON, GB AC= X57663. Sorghum vulgare mRNA for glycine-rich RNA-binding protein (clone S1) abstract	4
A	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 26 August 1991 (1991-08-26), XP002128338 HINXTON, GB AC= AF010580. Oryza sativa glycine-rich protein (OSGRP2) mRNA, complete cds. abstract	4
P, X	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 22 August 1999 (1999-08-22), XP002128339 HINXTON, GB AC = AI948280. Zea mays cDNA, mRNA sequence. EST sequence. abstract	1,2


Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9402619 A	03-02-1994	US 5401836 A AT 166108 T AU 672618 B AU 4673893 A BR 9306737 A CA 2140014 A DE 69318558 D DE 69318558 T EP 0651813 A JP 8501923 T MX 9304285 A NZ 254577 A	28-03-1995 15-05-1998 10-10-1996 14-02-1994 08-12-1998 03-02-1994 18-06-1998 10-09-1998 10-05-1995 05-03-1996 29-07-1994 25-06-1996
EP 0337532 A	18-10-1989	NL 8800725 A DE 68928892 D DE 68928892 T JP 2042991 A US 5057422 A	16-10-1989 18-02-1999 05-08-1999 13-02-1990 15-10-1991
US 5633363 A	27-05-1997	NONE	

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 23143 WO		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP99/06692	International filing date (day/month/year) 10/09/1999	Priority date (day/month/year) 11/09/1998	
International Patent Classification (IPC) or national classification and IPC C07K14/43			
Applicant AGRICULTURAL TECHNOLOGY & GENETICS GMBH et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 5 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none">I <input checked="" type="checkbox"/> Basis of the reportII <input type="checkbox"/> PriorityIII <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicabilityIV <input type="checkbox"/> Lack of unity of inventionV <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statementVI <input type="checkbox"/> Certain documents citedVII <input type="checkbox"/> Certain defects in the international applicationVIII <input checked="" type="checkbox"/> Certain observations on the international application			
Date of submission of the demand 03/03/2000		Date of completion of this report 11.01.01	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer Wimmer, G Telephone No. +49 89 2399 7347	



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/06692

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

Description, pages:

1-44 as originally filed

Claims, No.:

1-29 as received on 04/12/2000 with letter of 04/12/2000

Drawings, sheets:

1/5-5/5 as originally filed

Sequence listing part of the description, pages:

37-44, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/06692

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-3, 10-17, 20, 22-29
	No:	Claims	4-9, 18-19, 21
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-29
Industrial applicability (IA)	Yes:	Claims	
	No:	Claims	24, 27, 28

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item V

Reasoned statement under Art. 35(2) PCT with regard to novelty, inventive step or industrial applicability.

The application does not meet the requirements of Art. 33 PCT since **claims 4-9, 18-19 and 21 are not novel**, and **claims 1-29 do not appear to contain an inventive step**.

1) Reference is made to the following document:

D1: GODDEMEIER M L ET AL., : 'Root-specific expression of a *Zea mays* gene encoding a novel glycine-rich protein, zmGRP3.' PLANT MOLECULAR BIOLOGY, vol. 36, no. 5, March 1998 (1998-03), page 799-802 XP002128334

The validity of the priority date claimed for sequences SEQ ID NOs 1-15 has not been assessed. In case priority is later found to be invalid, document D6 as listed in the international search report (XP002128339) would be regarded as prior art for the purpose of examination of the claims.

Novelty under Art. 33(2) PCT.

- 2) Nucleic acid sequences of 70% or more identity to any of the sequences SEQ ID NOs 1-11 do not appear to be disclosed in the prior art. Consequently, claims 1-3 can be regarded as novel.
- 3) Document D1 discloses the entire *Zea mays* zmGRP3 gene, including some of the 3' untranslated region. This latter region is >87% identical to sequences overlapping with 413 bases of SEQ IDs 12 and 13.
Since the sequence of D1 therefore contains a subsequence which is >80% identical to the entire 440 bases of SEQ ID 13, claim 4 in its second aspect is not novel.
- 4) Consequently, the sequence of D1 also anticipates claims 5-8, since the sequence described had to be cloned using vectors; claims 5-8 therefore lack novelty.
Likewise, claim 9 is not novel, since also the zmGRP3 gene can be viewed as conferring "a character of agronomic or industrial benefit".
- 5) According sequences, linked to one of the genes listed in claim 10, have not been

disclosed. Also, additional regulatory elements were not described for the vector of D1. Claims 10-17 can therefore be regarded as novel.

Since the vector of D1 was obviously introduced into bacterial cells, claims 18, 19 and 21 lack novelty.

Claims 20 and 22-29 can be regarded as novel.

Inventive Step under Art. 33(3) PCT.

- 6) Claim 1 is directed to sequences which are 5' of the coding region of the *Zea mays* zmGRP3 gene.

Document D1 already discloses the coding region of this gene, and some of the 3' untranslated region. The authors of D1 describe this gene to be specifically expressed in the root system. The difference, and therefore the technical problem solved by the application, was to provide the regulatory sequences responsible for this effect.

However, the solution, the provision of 5' and 3' untranslated regions, cannot be viewed as being inventive.

It is common knowledge that sequences which act regulatory to the expression of a given gene are found primarily in the 5' and 3' untranslated regions, since promoter structures, polyadenylation and other signal sequences are found in those regions. The skilled person would therefore use standard techniques, based on sequences as disclosed in D1, to isolate genomic 5' and 3' sequences of the gene. The skilled person would then use these sequences to test the expression of a reporter gene in various plant tissues.

No inventive step can therefore be acknowledged for the provision of sequences SEQ IDs 1-15. Consequently, claims 1-5 lack an inventive step.

- 7) Additional features in claims 6-23 are trivial extensions, and do not make these claims inventive. Likewise, methods according to claims 24-29 represent obvious applications, and are not inventive.

Industrial Applicability under Art. 33(4) PCT.

- 8) Although humans were apparently not intended as target organisms for the methods of claims 24, 27 and 28, they are not explicitly excluded. This is considered to be contrary to morality and hence not allowable.

Re Item VIII

Certain observations and clarity.

The feature of claim 5, "which is derived from maize", does not define subject-matter since a given nucleic acid is defined by its nucleotide sequence, and the product does not allow to determine from which organism it was originally isolated.

Furthermore, the term "derived from" is ambiguous, since without further limitation, basically *any* nucleotide sequence can be regarded to be derived from any other.